# VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 15 (1-12 julio / 2022)

## EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas covid.
- Patentes más recientes en Patentscope sobre vacunas.
- Patentes más recientes en USPTO sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT



CUBA

# Noticias en la Web

## Euroimmun lanza dos ensayos para la cuantificación de anticuerpos contra el SARS-CoV-2



**1 jun**. Euroimmun, una empresa de PerkinElmer, Inc., ha anunciado el lanzamiento de dos ensayos con la marca CE: el Anti-SARS-CoV-2 RBD ChLIA (IgG) y el Anti-SARS-CoV-2 Ómicron ELISA (IgG). Ambas pruebas permiten la detección de anticuerpos IgG formados contra el SARS-CoV-2 y están disponibles para los laboratorios de los países que aceptan la marca CE.

Las investigaciones demuestran que las respuestas inmunitarias a la infección por el SARS-Cov-2, que suelen medirse mediante títulos de anticuerpos neutralizantes, pueden variar mucho entre las personas. Comprender cómo disminuyen los niveles de anticuerpos a lo largo del tiempo en determinados individuos y poblaciones podría ayudar a responder a cuestiones epidemiológicas, clínicas y virológicas fundamentales, incluidas las que conducen a limitar la transmisión del virus y a seguir desarrollando vacunas y terapias contra el COVID-19.

El Anti-SARS-CoV-2 RBD ChLIA (IgG) permite la medición cuantitativa de los anticuerpos IgG formados contra el dominio de unión al receptor (RBD) del SARS-CoV-2. Al hacerlo, ofrece la posibilidad de convertir la concentración de anticuerpos determinada en unidades estandarizadas (BAU/ml). Este ensayo es adecuado para la determinación de las respuestas de anticuerpos IgG tanto después de la infección como de la vacunación con una vacuna basada en la proteína recombinante de la espícula. Euroimmun también ofrece el sistema automatizado multidisciplinar IDS-i10 e IDS-iSYS que permite el procesamiento automatizado de inmunoensayos de quimioluminiscencia como éste.

Del mismo modo, el ELISA Anti-SARS-CoV-2 Omicron (IgG) complementa la cartera de productos diagnósticos para el SARS-CoV-2 de EUROMMUN. Dado que Omicron sigue siendo la variante dominante del SARS-CoV-2 en muchos países del mundo, este ensayo se basa en la subunidad S1 recombinante de la proteína de la espícula de dicha variante del SARS-CoV-2, y puede utilizarse para cuantificar los anticuerpos IgG formados contra el virus.

Fuente: PHARMATECH. Disponible en https://bit.ly/3PmKk6V

## ¿Por qué Ómicron tiene tantas subvariantes?

**3 jun**. La variante Ómicron SARS-CoV-2 ha cambiado el curso de la pandemia y ha llevado a un aumento dramático de los casos en todo el mundo. Es una variante con la que estamos familiarizados pero, también escuchamos cada vez más los nombres de nuevas subvariantes de ómicron como BA.2, BA.4 y ahora BA.5.

¿Por qué estamos viendo más de estas nuevas subvariantes? La preocupación con estas subvariantes es que pueden hacer que las personas se vuelvan a infectar, lo que lleva a otro aumento en los casos.

**¿Por qué hay tantos tipos de Ómicron?**

Al igual que todos el virus, el SARS-CoV-2, muta constantemente. La gran mayoría de las mutaciones tienen

  

poco o ningún efecto sobre la capacidad del virus para transmitirse de una persona a otra o causar una enfermedad grave.

Cuando un virus acumula una cantidad sustancial de mutaciones, se considera un linaje diferente, como una rama diferente en un árbol genealógico, aunque un linaje viral no se etiqueta como variante hasta que haya acumulado varias mutaciones únicas conocidas por mejorar la capacidad del virus para transmitir y/o causar una enfermedad más grave.

Es lo que ha ocurrido con el linaje BA, que la Organización Mundial de la Salud denominó ómicron. Dado que Ómicron se ha expandido y ha tenido muchas oportunidades de mutar, también ha adquirido mutaciones específicas propias. Estas han dado lugar a varios sublinajes o subvariantes.

Las dos primeras subvariantes fueron etiquetadas como BA.1 y BA.2. La lista actual ahora también incluye BA.1.1, BA.3, BA.4 y BA.5.

Las subvariantes BA.4 y BA.5, son particularmente efectivas para reinfectar a personas con infecciones previas de BA.1 u otros linajes. Además, existe la preocupación de que estas subvariantes puedan infectar a las personas que han sido vacunadas. Se espera que debido a las reinfecciones se experimente un rápido aumento de los casos de covid en las próximas semanas.

**¿Está el virus mutando más rápido?**

Según muestra una investigación, el SARS-CoV-2 hace "carreras de velocidad mutacionales" durante cortos períodos de tiempo. Durante una de estas carreras de velocidad, el virus puede mutar cuatro veces más rápido de lo normal durante unas pocas semanas.

No está claro por qué el virus sufre estas carreras mutacionales que conducen a la aparición de variantes, pero existen dos teorías sobre los orígenes de Ómicron y cómo acumuló tantas mutaciones.

La primera es que el virus podría haber evolucionado en infecciones crónicas en personas inmunodeprimidas y en segundo lugar, el virus podría haber "saltado" a otra especie, antes de volver a infectar a los humanos.

Fuente: Onda Cero. Disponible en https://bit.ly/3O7Ag0C

## Cuarta dosis de vacuna COVID: protección "fuerte" pero con una duda clave

**7 jul**. La aplicación de una cuarta dosis de la vacuna contra la COVID-19 ha demostrado ser eficaz para inmunizar frente a la variante Ómicron a colectivos de riesgo como las personas mayores que viven en residencias de la tercera edad. Un estudio canadiense ha confirmado que esta inyección de refuerzo adicional desencadena una “fuerte protección” en este grupo demográfico, aunque no ha logrado despejar algunas de las incógnitas que todavía baraja la comunidad científica.

La investigación liderada por el epidemiólogo Jeffrey C. Kwong se diseñó para medir la efectividad de la cuarta dosis de las vacunas de Pfizer y de Moderna a la hora de frenar las infecciones, la aparición de

  

síntomas y la evolución grave de la enfermedad. En total, se recurrió a una muestra de 61.344 personas de más de 60 años de edad que son usuarios de 626 residencias de Ontario, la capital canadiense.



Los resultados publicados en la revista académica The BMJ han apuntado a que la nueva inyección de refuerzo fue capaz de elevar hasta un 19 por ciento la eficacia de la pauta para evitar nuevos contagios, un 31 por ciento para reducir la aparición de síntomas y un 40 por ciento para proteger ante la aparición de síntomas graves que pueden terminar produciendo un ingreso o un fallecimiento.

Los datos también muestran que la pauta de cuatro inyecciones presenta una alta eficacia también en comparación con aquellas personas que no han se han vacunado en ningún momento desde que arrancaron las campañas a escala global. Su capacidad para frenar las infecciones es del 49 por ciento en términos generales. Mientras que es capaz de reducir hasta en un 69 por ciento de los casos los síntomas y en un 86 por ciento las complicaciones severas de salud.

El estudio se ha llevado a cabo entre el 30 de diciembre de 2021 y el 27 de abril del 2022 en un momento marcado por la entrada de Ómicron que se convirtió rápidamente en la variante dominante en Canadá. Los autores perseguían conocer si el refuerzo de la pauta era efectivo para contrarrestar la "evasión inmunitaria parcial" provocada por la nueva cepa en un momento de incertidumbre.

"Ómicron generó preocupaciones para las poblaciones de atención a largo plazo, con evidencia preliminar que sugiere una mayor transmisibilidad, un mayor riesgo de reinfección y una menor protección de la vacuna", han recordado los autores.

Este estudio se ha alineado de esta manera con otras investigaciones internacionales publicadas en las últimas semanas. Un análisis realizado en Israel ya apuntó a que la cuarta dosis de la vacuna de Pfizer provocaba una protección adicional "considerable" frente a la infección de Ómicron, en comparación con la tercera inyección recibida meses antes.

**¿Cuánto tiempo me va a proteger la cuarta vacuna COVID?**

A pesar de este importante hallazgo, los autores de la investigación han reconocido que sigue habiendo una incógnita que no han logrado despejar: el tiempo exacto que permanece la inmunidad. "Una cuarta dosis de vacuna se asoció con una fuerte protección contra resultados graves en los residentes vacunados en comparación con los residentes no vacunados, aunque se desconoce la duración de la protección", han subrayado.

Los investigadores han comprobado además que la efectividad fue menor cuando la cuarta dosis se aplicó con un espacio temporal inferior a los 84 días con respecto a la tercera. Esta idea refuerza la teoría de que es mejor dilatar al menos durante tres meses la pauta, pero tampoco han dado con un punto exacto. "Se desconoce el intervalo de dosificación óptimo", han agregado.

Fuente: Redacción Médica. Disponible en https://bit.ly/3yBPW6K

  

# La respuesta inmune por vacuna COVID, "independiente" a la que crea trombos

**8 jul**. Una nueva investigación internacional ha demostrado que no existe relación directa entre la vacunación contra la COVID-19 y un mayor riesgo de padecer una trombosis. Así, los científicos sostienen que las respuestas inmunitarias frente a la proteína espiga del SARS-CoV-2 (inducida por la COVID-19 o cualquiera de las vacunas contra el Covid-19) y la del factor 4 antiplaquetario activador de plaquetas (PF4) son independientes.

En concreto, el estudio publicado en la revista *The New England Journal of Medicine*, señala como los pacientes que habían contraído COVID-19 durante la investigación "no desarrollaron aumentos importantes en los niveles de anticuerpos PF4 después de la recuperación de COVID-19".

Para llevar a cabo el estudio, los investigadores se basaron en la posible relación entre las dosis contra el SARS-CoV-2 y el mayor riesgo de padecer trombocitopenia trombótica inmune inducida por la vacuna (VITT).

Así, siguiendo otras investigaciones anteriores, se planteaba la posibilidad de si existía un mayor riesgo de padecer una trombosis debido al aumento de los anticuerpos del factor PF4 de la clase de inmunoglobulina G. Estos anticuerpo apenas "estarían presente en las vacunas contra la COVID-19 basadas en vectores de adenovirus, como podrían ser las de AstraZeneca y Johnson & Johnson/Janssen", lo que suma a los resultados de la investigación la recomendación de administrar las vacunas contra el SARS-CoV-2 basadas en ARNm a los pacientes con antecedentes de VITT.

**¿Qué relación hay entre la vacuna covid y la trombosis?**

Siguiendo la relación entre las vacunas covid y los anticuerpo PF4, los investigadores también han podido mostrar que en los hallazgos "in vitro la COVID-19 no se reestimula los anticuerpos anti-PF4 en pacientes con antecedentes de VIT" lo que permitiría reforzar la recomendación de administrar la dosis de refuerzo con vacunas basadas en ARN en los casos sospechosos de generar trombosis.

"Ningún paciente tuvo trombocitopenia recurrente, una nueva trombosis tras la activación plaquetaria por ser positivo. Nuestras conclusiones muestran que las respuestas inmunitarias frente a la proteína espiga del SARS-CoV-2 (inducida por el Covid-19 o cualquiera de las vacunas contra el Covid-19) y frente al activador de plaquetas (inducida en asociación con VITT) son independientes. Es decir, la COVID-19 no reestimula los anticuerpos en pacientes con principio de trombosis", zanja el estudio.

**"La COVID-19 no reestimula los anticuerpos en pacientes con principio de trombosis".**

**¿Qué efectos adversos tienen las vacunas COVID-19?**

Pese a que este estudio, en el que se ha contado una muestra de 70 pacientes, no se ha hallado una relación directa entre las vacunas covid de ARNm y los trombos. Desde el Ministerio de Sanidad sí ha informado de la aparición del síndrome de trombosis con trombocitopenia (formación de coágulos de sangre en los vasos sanguíneos con niveles bajos de plaquetas en la sangre) en casos contados en las vacunas covid de Astrazeneca y Janssen. En este sentido, advierte que se trata de un efecto adverso de las vacunas covid que "muy raramente" se presenta.

De este modo, confirma que se trata de un trastorno que se presenta en la mayor parte de los casos tras la administración de la primera dosis de Astrazeneca. Y especifica que, de los 1.809 casos notificados

  

mundialmente, 1.643 se notificaron con la primera dosis y 166 con la segunda.

**¿Los casos de trombosis son más propicios en mujeres?**

En este sentido, diferentes organismos oficiales sí han descartado ya que esta afección se acentúe entre las mujeres como se había pensado hasta ahora con el compuesto de Janssen. "En base a una revisión actualizada de la información disponible, se ha concluido que la diferencia de casos notificados entre sexos parece menor de lo que se había observado inicialmente", defiende el Ministerio de Sanidad al respecto.

Fuente: Redacción Médica. Disponible en https://bit.ly/3IAEaxY

## Hipra se acerca al veredicto de la primera vacuna española frente a la COVID-19


**9 jul**. La vacuna del laboratorio Hipra frente a la COVID-19 encara sus últimos días antes de su posible aprobación. La Agencia Europea del Medicamento (EMA, en sus siglas en inglés) ha recibido los últimos datos exigidos a la farmacéutica gerundense y el organismo podría dar un veredicto sobre el producto en las sesiones del 18 al 21 de julio, según informan fuentes sanitarias.

La ministra de Ciencia e Innovación, Diana Morant, reforzó ayer esa idea que se maneja en el sector farmacéutico en España al indicar que espera que “en pocos días” se conozca la respuesta de EMA.

En estos días previos se reúnen los expertos del comité de productos biológicos de la EMA para analizar si Hipra ha aportado todos los datos clínicos e industriales. Inicialmente, se preveía que la vacuna pudiese ser aprobada en junio, pero la compañía ha tenido que enviar más aclaraciones, en un proceso habitual en la aprobación de cualquier medicamento.

La empresa de la familia Nogareda ha enviado todos los datos solicitados por la EMA para que sean revisados por los expertos del comité de productos biológicos.

Si este comité considera que cuenta con los datos suficientes, pasará al siguiente nivel en la EMA, que es la última barrera, concretamente el comité de productos médicos para uso humano (CHMP, en sus siglas en inglés). Está previsto que estos expertos se reúnan del 18 al 21 de julio y podrían ya en esos días analizar los datos y decidir si la vacuna española recibe el visto bueno. Después de esa etapa, únicamente quedaría la aprobación definitiva en las horas o días posteriores de la Comisión Europea, que suele refrendar lo aprobado en el CHMP.

La farmacéutica ha presentado su alternativa como *booster* o dosis de refuerzo para las personas anteriormente vacunadas, lo que permitiría que si se aprueba en los próximos días, pueda utilizarse en otoño dentro de la estrategia vacunal de los países europeos. Otras compañías como Sanofi también trabajan en un *booster* y Pfizer/BioNTech y Moderna también esperan respuestas sobre sus últimas versiones frente a las variantes de este coronavirus.

Desde la EMA se responde a este diario que mientras el proceso siga su curso no pueden informar sobre la

  

fecha en la que el CHMP analizará la eficacia del producto de Hipra y explican que el 18 de julio se conocerá la agenda de temas a tratar y si está incluida la vacuna española. En cualquier caso, si la agencia lo considera, podría convocar una reunión extraordinaria, como ya hizo en el pasado en otras alternativas frente a la COVID-19. Desde Hipra se declinó comentar el asunto.

"La ciencia tiene sus tiempos, dejemos que el tiempo de la ciencia se cumpla", aseguró Morant, respecto a la aprobación de la investigación de Hipra, recoge Efe. "El pronóstico que tenían era junio (...), espero que en pocos días tengamos la respuesta por parte de la EMA y que tengamos una vacuna española que habrá desarrollado capacidades que ya se quedan en nuestro país y que son buenas para futuros retos", agregó.

Desde el pasado 29 de marzo, el producto de Hipra está inmerso en lo que se conoce como un proceso de revisión continua, que evalúa los datos existentes a medida que se van generando (para avanzar rápidamente), en el que se analizan los estándares sobre eficacia, seguridad y calidad. Hipra deberá demostrar mejoras sobre las alternativas que ya se utilizan masivamente como la de Pfizer/BioNTech.

**La única española**

Hipra está desarrollando la fase III (últimos ensayos clínicos) con 3.000 voluntarios en España, Italia y Portugal. Esta vacuna está basada en proteína recombinante. La EMA indicó en marzo que los resultados preliminares sugieren que la respuesta inmunitaria puede ser eficaz contra el SARS-CoV-2, incluidas variantes como Ómicron.

La vacuna de Hipra es la única española que ha superado la fase de I+D en laboratorio y que, por tanto, se ha probado con voluntarios. Otras alternativas, por ejemplo las de investigación pública del CSIC, se han quedado estancadas por el momento. Este laboratorio está especializado en productos para salud animal y se trata de su primera solución para humanos.

Fuente: MSN. Disponible en https://bit.ly/3O6t8BP

## Estos son los nuevos síntomas de la COVID-19 en julio de 2022

**11 jul**. Las nuevas variantes del coronavirus han duplicado los contagios en la séptima ola. En las últimas semanas ha habido un repunte de positivos y la comunidad sanitaria ya ha expresado su preocupación. "La pandemia está aun entre nosotros. Los números están de nuevo en fuerte aumento en Europa", ha alertado la comisaria de Salud de la Unión Europea, Stella Kyriakides.

En este sentido, la Organización Mundial de la Salud (OMS) ha admitido que con la llegada del verano y un mayor flujo de movimiento esperaba "altos niveles" de COVID-19 en Europa. "Estos aumentos se están produciendo a pesar de las reducciones en las pruebas en algunos países, lo que significa que los casos que estamos viendo son solo la punta del iceberg", ha explicado Tedros Adhanom Ghebreyesus, director general del organismo.

La realidad es que el 'boom' ha llegado de nuevo al continente, y especialmente a países como Francia, Italia y España. En nuestro país es especialmente notable en los mayores de 60 años, cuya incidencia es más elevada.

**Síntomas del COVID-19**

A pesar del drástico incremento de infecciones, lo cierto es que los síntomas de la COVID-22 son más leves que los de las variantes antecesoras, pero duran más tiempo, hasta 7 días. Entre ellos se encuentran la tos,

  

fatiga, congestión nasal, dolor de garganta y cefalea. Además, los últimos estudios indican que estas subvariantes atacan más al aparato digestivo.

"A día de hoy, el SARS-CoV-2 produce una infección viral, como si se tratara de un catarro, y menos agresivo", detalla Marcos López Hoyos, presidente de la Sociedad Española de Inmunología.

Positividad retrasada

Lo curioso es que la expansión descontrolada de los BA.4 y BA.5, que escapan con mayor facilidad a la inmunidad de la vacuna, muestran una positividad retrasada. Así, los test de antígenos no detectan tan rápido la nueva variante del coronavirus, lo que provoca que muchos den por descartado el contagio de coronavirus y sigan haciendo vida normal.

Fuente: Antena 3. Disponible en https://bit.ly/3AT0Zeq

## Nueva versión de vacuna Covid Moderna responde mejor contra variante Ómicron


**11 jul**. El laboratorio Moderna aseguró el lunes que su nueva versión de refuerzo de la vacuna contra la COVID-19, que todavía está en periodo de prueba, ha "demostrado una respuesta de anticuerpos neutralizantes significativamente más alta contra las subvariantes BA. 4 y 5 de Ómicron en comparación con el refuerzo actualmente autorizado".

Según EFE, los resultados fueron consistentes en todos los grupos de edad, incluidos los mayores de 65 años, independiente de si habían sido contagiados previamente o no. El director ejecutivo de Moderna, Stéphane Bancel, declaró que se encuentran trabajando en dos versiones de una vacuna, de acuerdo con las “recomendaciones recientes de la Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por su sigla en inglés)”.

Según Bancel, el desarrollo de estas dos versiones responde a las “diferentes preferencias del mercado para las subvariantes de ómicron, los requisitos de los datos clínicos y la urgencia de comenzar campañas de refuerzo en octubre de poblaciones vulnerables".

Fuente: La República. Disponible en https://bit.ly/3aDxT8d

## Llamamiento urgente para mejorar el uso de las vacunas existentes y desarrollar otras nuevas con el fin de luchar contra la resistencia a los antimicrobianos

**12 jul**. La Organización Mundial de la Salud ha publicado hoy el primer informe de su historia sobre las vacunas actualmente en desarrollo para prevenir las infecciones causadas por patógenos bacterianos resistentes a los antimicrobianos. El análisis de la OMS señala la necesidad de acelerar los ensayos de las vacunas contra patógenos resistentes a los antimicrobianos que se encuentran en las últimas fases de desarrollo y maximizar el uso de las vacunas existentes.

La pandemia silenciosa de la resistencia a los antimicrobianos (RAM) es un gran problema de salud pública que va en aumento. Las infecciones bacterianas resistentes están asociadas por si solas a casi 4,95

  

millones de muertes al año, de las que 1,27 millones se atribuyen directamente a la RAM. Pero la RAM va más allá de las infecciones bacterianas. La RAM se produce cuando las bacterias, los virus, los hongos y los parásitos cambian con el tiempo y dejan de responder a los medicamentos. Cuando una persona se infecta con estos microbios, se dice que la infección es resistente a los medicamentos antimicrobianos. Estas infecciones suelen ser difíciles de tratar.

Las vacunas son, en primer lugar, herramientas poderosas para prevenir las infecciones y, por tanto, tienen el potencial de frenar la propagación de las infecciones resistentes a los antimicrobianos. El informe sobre las vacunas contra patógenos resistentes a los antimicrobianos tiene por objeto orientar las inversiones y la investigación en vacunas viables para mitigar la RAM.

En el análisis se identifican 61 vacunas candidatas en diversas fases de desarrollo clínico, entre ellas varias en las últimas fases de desarrollo, para hacer frente a las enfermedades provocadas por las bacterias que figuran en la lista de bacterias prioritarias a las que la OMS ha dado prioridad en materia de I+D. Aunque en el informe se indica que estas vacunas candidatas en fases avanzadas tienen una gran viabilidad de desarrollo, también se advierte de que la mayoría de ellas no estarán disponibles en breve.

Organización Mundial de la Salud

«Prevenir las infecciones mediante la vacunación reduce el uso de antibióticos, que es uno de los principales factores que propician la RAM. Sin embargo, de los seis principales patógenos bacterianos responsables de las muertes debidas a la RAM, solo uno, la enfermedad neumocócica (Streptococcus pneumoniae), tiene una vacuna,» dijo la Dra. Hanan Balkhy, Subdirectora General de Resistencia a los Antimicrobianos de la OMS. «Se necesita urgentemente un acceso asequible y equitativo a las vacunas que salvan vidas, como las vacunas antineumocócicas, para reducir el número de muertes y mitigar el aumento de la RAM,» añadió.

En el informe se pide un acceso equitativo a nivel mundial a las vacunas que ya existen, especialmente entre las poblaciones que más las necesitan en entornos con recursos limitados. Ya existen vacunas contra cuatro enfermedades provocadas por bacterias prioritarias: la enfermedad neumocócica (Streptococcus pneumoniae), el Hib (Haemophilus influenzae de tipo b), la tuberculosis (mycobacterium tuberculosis) y la fiebre tifoidea (Salmonella Typhi). Las actuales vacunas de Bacillus Calmette-Guérin (BCG) contra la tuberculosis no protegen adecuadamente contra la tuberculosis, por lo que debería acelerarse el desarrollo de vacunas más eficaces contra esta enfermedad. Las tres vacunas restantes son eficaces, y debemos aumentar el número de personas que las reciben para contribuir a reducir el uso de antibióticos y evitar más muertes.

Un aspecto que cabe destacar con respecto a la lucha mundial contra la RAM es que las bacterias incluidas en la lista de patógenos prioritarios, pese a suponer una importante amenaza para la salud pública precisamente por su resistencia a los antibióticos, cuentan en la actualidad con un pequeño número de vacunas candidatas en proceso de desarrollo, cuya viabilidad no es además muy alta. Es poco probable que se disponga de vacunas contra estos patógenos a corto plazo, por lo que deben buscarse urgentemente intervenciones alternativas para prevenir las infecciones resistentes debidas a los patógenos bacterianos prioritarios.

  

«Se necesitan enfoques disruptivos para enriquecer la línea de producción y acelerar el desarrollo de vacunas. Las enseñanzas extraídas del desarrollo de las vacunas anti-COVID-19 y de las vacunas de ARNm ofrecen oportunidades únicas para explorar el desarrollo de vacunas contra las bacterias,» ha dicho el Dr. Haileyesus Getahun, Director del Departamento de Coordinación y Alianzas Mundiales contra la RAM de la OMS.

En el informe se examinan algunos de los retos a los que se enfrentan la innovación y el desarrollo de vacunas, incluso en lo referente a los patógenos asociados a las infecciones nosocomiales. Uno de esos retos es la dificultad para definir a la población objetivo entre todos los pacientes hospitalizados; el costo y la complejidad de los ensayos de eficacia de las vacunas; y la falta de precedentes regulatorios y/o normativos para las vacunas contra las infecciones nosocomiales.

«El desarrollo de vacunas es costoso y supone un reto científico, a menudo con altas tasas de fracaso; por otro lado, para las vacunas candidatas que cumplen el proceso con éxito, los complejos requisitos regulatorios y de fabricación requieren más tiempo. Tenemos que aprovechar las lecciones extraídas del desarrollo de las vacunas anti-COVID-19 y acelerar la búsqueda de vacunas para hacer frente a la RAM,» dijo la Dra. Kate O'Brien, Directora del Departamento de Inmunización, Vacunas y Productos Biológicos de la OMS.

Fuente: Organización Mundial de la Salud OMS. Disponible en https://bit.ly/3PuDPiL



  

# Artículos científicos publicados en Medline

*Filters activated: Publication date from 2022/07/0*1 to 2022/07/11. "Covid Vaccine" (Title/Abstract) 227 records.

**Covid-19** vaccines and variants of concern: A review.
Hadj Hassine I. Rev Med Virol. 2022 Jul;32(4):e2313. doi: 10.1002/rmv.2313. Epub 2021 Nov 9. PMID: 34755408

Current evidence on efficacy of **COVID-19** booster dose vaccination against the Omicron variant: A systematic review.
Chenchula S, Karunakaran P, Sharma S, Chavan M. J Med Virol. 2022 Jul;94(7):2969-2976. doi: 10.1002/jmv.27697. Epub 2022 Mar 14. PMID: 35246846

mRNA cancer vaccines: Advances, trends and challenges.
He Q, Gao H, Tan D, Zhang H, Wang JZ. Acta Pharm Sin B. 2022 Jul;12(7):2969-2989. doi: 10.1016/j.apsb.2022.03.011. Epub 2022 Mar 23. PMID: 35345451

**COVID-19 vaccine** hesitancy.
Dubé E, MacDonald NE. Nat Rev Nephrol. 2022 Jul;18(7):409-410. doi: 10.1038/s41581-022-00571-2. PMID: 35414006

**COVID-19 Vaccine** Provider Availability and Vaccination Coverage Among Children Aged 5-11 Years - United States, November 1, 2021-April 25, 2022.
DeCuir J, Meng L, Pan Y, Vogt T, Chatham-Stevens K, Meador S, Shaw L, Black CL, Harris LQ. MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):847-851. doi: 10.15585/mmwr.mm7126a3. PMID: 35771688

The level and determinants of **COVID-19 vaccine** acceptance in Ghana.
Okai GA, Abekah-Nkrumah G. PLoS One. 2022 Jul 8;17(7):e0270768. doi: 10.1371/journal.pone.0270768. eCollection 2022. PMID: 35802742

Effectiveness of BNT162b2 **vaccine** against SARS-CoV-2 infection and severe **COVID-19** in children aged 5-11 years in Italy: a retrospective analysis of January-April, 2022.
Sacco C, Del Manso M, Mateo-Urdiales A, Rota MC, Petrone D, Riccardo F, Bella A, Siddu A, Battilomo S, Proietti V, Popoli P, Menniti Ippolito F, Palamara AT, Brusaferro S, Rezza G, Pezzotti P, Fabiani M; Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry. Lancet. 2022 Jul 9;400(10346):97-103. doi: 10.1016/S0140-6736(22)01185-0. Epub 2022 Jul 1. PMID: 35780801

Parental **vaccine** hesitancy and concerns regarding the **COVID-19** virus.
Salazar TL, Pollard DL, Pina-Thomas DM, Benton MJ. J Pediatr Nurs. 2022 Jul-Aug;65:10-15. doi: 10.1016/j.pedn.2022.03.010. Epub 2022 Apr 1. PMID: 35367855

Systemic syndromes of rheumatological interest with onset after **COVID-19 vaccine** administration: a report of 30 cases.
Ursini F, Ruscitti P, Raimondo V, De Angelis R, Cacciapaglia F, Pigatto E, Olivo D, Di Cola I, Galluccio F, Francioso F, Foti R, Tavoni AG, D'Angelo S, Campochiaro C, Motta F, De Santis M, Bilia S, Bruno C, De Luca G, Visentini M, Ciaffi J, Mancarella L, Brusi V, D'Onghia M, Cuomo G, Fusaro E, Cipriani P, Dagna L,

  

Guiducci S, Meliconi R, Iannone F, Iagnocco A, Giacomelli R, Ferri C. Clin Rheumatol. 2022 Jul;41(7):2261-2267. doi: 10.1007/s10067-022-06078-2. Epub 2022 Jan 29. PMID: 35091783

Knowledge about **COVID-19 vaccine** and vaccination in Vietnam: A population survey.
Duong MC, Duong BT, Nguyen HT, Nguyen Thi Quynh T, Nguyen DP. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1197-1205.e4. doi: 10.1016/j.japh.2022.01.014. Epub 2022 Jan 19. PMID: 35151581

Addressing **vaccine** hesitancy and resistance for **COVID-19** vaccines.
Peters MDJ. Int J Nurs Stud. 2022 Jul;131:104241. doi: 10.1016/j.ijnurstu.2022.104241. Epub 2022 Apr 1. PMID: 35489108

Prior trauma exposure, posttraumatic stress symptoms, and **COVID-19 vaccine** hesitancy.
Nishimi K, Borsari B, Tripp P, Jiha A, Dolsen EA, Woolley JD, Neylan TC, O'Donovan A. J Psychiatr Res. 2022 Jul;151:399-404. doi: 10.1016/j.jpsychires.2022.05.003. Epub 2022 May 12. PMID: 35588548

Message framing and **COVID-19 vaccine** acceptance among millennials in South India.
Prakash A, Jeyakumar Nathan R, Kini S, Victor V. PLoS One. 2022 Jul 8;17(7):e0269487. doi: 10.1371/journal.pone.0269487. eCollection 2022. PMID: 35802760

Establishment and evaluation of scalable **COVID-19 vaccine** clinics at a large university.
Garofoli GK, Gálvez-Peralta M, Barrickman AL, Goodhart AL, Johnson H, McMillan AN, Elswick BM, Newmeyer ES, Burrell CN, Capehart KD, Petros WP. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1430-1437. doi: 10.1016/j.japh.2022.03.022. Epub 2022 Mar 31. PMID: 35461778

Audio Interview: Designing the Next **Covid-19 Vaccine**.
Rubin EJ, Baden LR, Morrissey S. N Engl J Med. 2022 Jul 7;387(1):e6. doi: 10.1056/NEJMe2209134. PMID: 35793212

Can **COVID-19** vaccines improve cardiovascular outcomes?
Kow CS, Ramachandram DS, Hasan SS. Travel Med Infect Dis. 2022 Jul-Aug;48:102350. doi: 10.1016/j.tmaid.2022.102350. Epub 2022 Apr 29. PMID: 35500844

**COVID-19 vaccine** behaviors and intentions among a national sample of United States adults ages 18-45.
Brownstein NC, Reddy H, Whiting J, Kasting ML, Head KJ, Vadaparampil ST, Giuliano AR, Gwede CK, Meade CD, Christy SM. Prev Med. 2022 Jul;160:107038. doi: 10.1016/j.ypmed.2022.107038. Epub 2022 Apr 7. PMID: 35398369

Prevalence and correlates of **COVID-19 vaccine** hesitancy among the elderly in Qatar: A cross-sectional study.
Abdul Karim M, Reagu SM, Ouanes S, Waheed Khan A, Smidi WS, Al-Baz N, Alabdulla M. Medicine (Baltimore). 2022 Jul 1;101(26):e29741. doi: 10.1097/MD.0000000000029741. PMID: 35777032

SARS-CoV-2-related and **Covid-19 vaccine**-induced thromboembolic events: A comparative review.
Afshar ZM, Barary M, Babazadeh A, Hosseinzadeh R, Alijanpour A, Miri SR, Sio TT, Sullman MJM, Carson-Chahhoud K, Langer F, Ebrahimpour S. Rev Med Virol. 2022 Jul;32(4):e2327. doi: 10.1002/rmv.2327. Epub 2022 Feb 3. PMID: 35112763

**COVID-19 vaccine** hesitancy in Malaysia: Exploring factors and identifying highly vulnerable groups.
Jafar A, Dambul R, Dollah R, Sakke N, Mapa MT, Joko EP. PLoS One. 2022 Jul 8;17(7):e0270868. doi: 10.1371/journal.pone.0270868. eCollection 2022. PMID: 35802652

Efficacy of **COVID-19** vaccines by race and ethnicity.
Salari N, Vepa A, Daneshkhah A, Darvishi N, Ghasemi H, Khunti K, Mohammadi M. Public Health. 2022 Jul;208:14-17. doi: 10.1016/j.puhe.2022.04.009. Epub 2022 May 5. PMID: 35660280

Association of initial **COVID-19 vaccine** hesitancy with subsequent vaccination among pregnant and postpartum individuals.
Germann K, Kiefer MK, Rood KM, Mehl R, Wu J, Pandit R, Lynch CD, Landon MB, Grobman WA, Costantine MM, Venkatesh KK. BJOG. 2022 Jul;129(8):1352-1360. doi: 10.1111/1471-0528.17189. Epub 2022 May 19. PMID: 35429081

The 'Fauci Effect': Reducing **COVID-19** misconceptions and **vaccine** hesitancy using an authentic multimodal intervention.
Johnson V, Butterfuss R, Kim J, Orcutt E, Harsch R, Kendeou P. Contemp Educ Psychol. 2022 Jul;70:102084. doi: 10.1016/j.cedpsych.2022.102084. Epub 2022 Jun 23. PMID: 35765462

Narrative Messages, Information Seeking and **COVID-19 Vaccine** Intention: The Moderating Role of Perceived Behavioral Control.
Borah P, Xiao X, Lee DKL. Am J Health Promot. 2022 Jul;36(6):923-933. doi: 10.1177/08901171221075019. Epub 2022 Mar 25. PMID: 35081757

**COVID-19 Vaccine** Uptake Among People Living with HIV.
Menza TW, Capizzi J, Zlot AI, Barber M, Bush L. AIDS Behav. 2022 Jul;26(7):2224-2228. doi: 10.1007/s10461-021-03570-9. Epub 2022 Jan 7. PMID: 34994913

Perceptions and Attitudes toward **COVID-19** Vaccination among Pregnant and Postpartum Individuals.
Siegel MR, Lumbreras-Marquez MI, James K, McBay BR, Gray KJ, Schantz-Dunn J, Diouf K, Goldfarb IT. Am J Perinatol. 2022 Jul 10. doi: 10.1055/a-1877-5880. Online ahead of print. PMID: 35709744

A Review on Immunological Responses to SARS-CoV-2 and Various **COVID-19 Vaccine** Regimens.
Upreti S, Samant M. Pharm Res. 2022 Jul 1:1-16. doi: 10.1007/s11095-022-03323-w. Online ahead of print. PMID: 35773445

**COVID-19 Vaccine** Hesitancy and Early Adverse Events Reported in a Cohort of 7,881 Italian Physicians.
Monami M, Gori D, Guaraldi F, Montalti M, Nreu B, Burioni R, Mannucci E. Ann Ig. 2022 Jul-Aug;34(4):344-357. doi: 10.7416/ai.2021.2491. Epub 2021 Nov 30. PMID: 34821928

SARS-CoV-2 **vaccine**-associated subacute thyroiditis.
Yorulmaz G, Sahin Tekin M. J Endocrinol Invest. 2022 Jul;45(7):1341-1347. doi: 10.1007/s40618-022-01767-w. Epub 2022 Feb 19. PMID: 35182366

BNT162b2 mRNA **COVID-19 vaccine** and booster in patients with autoimmune rheumatic diseases: a national cohort study.

Bieber A, Sagy I, Novack L, Brikman S, Abuhasira R, Ayalon S, Novofastovski I, Abu-Shakra M, Mader R. Ann Rheum Dis. 2022 Jul;81(7):1028-1035. doi: 10.1136/annrheumdis-2021-221824. Epub 2022 Apr 13. PMID: 35418481

**COVID-19 vaccine** and pregnancy outcomes: a systematic review and meta-analysis.
Carbone L, Trinchillo MG, Di Girolamo R, Raffone A, Saccone G, Iorio GG, Gabrielli O, Maruotti GM. Int J Gynaecol Obstet. 2022 Jul 10. doi: 10.1002/ijgo.14336. Online ahead of print. PMID: 35810414

The Influence of Information Source on **COVID-19 Vaccine** Efficacy and Motivation for Self-Protective Behavior.
Muturi N. J Health Commun. 2022 Jul 6:1-9. doi: 10.1080/10810730.2022.2096729. Online ahead of print. PMID: 35793310

Examining the direct and indirect effects of trust in motivating **COVID-19 vaccine** uptake.
Liu S, Chu H. Patient Educ Couns. 2022 Jul;105(7):2096-2102. doi: 10.1016/j.pec.2022.02.009. Epub 2022 Feb 12. PMID: 35181177

The vaccination status and adverse effects of **COVID-19 vaccine** among pregnant women in Japan in 2021.
Komine-Aizawa S, Haruyama Y, Deguchi M, Hayakawa S, Kawana K, Kobashi G, Miyagi E, Yamada H, Sugiyama T. J Obstet Gynaecol Res. 2022 Jul;48(7):1561-1569. doi: 10.1111/jog.15285. Epub 2022 May 10. PMID: 35537777

The S-Trimer (SCB-2019) **COVID-19 vaccine** and reinfection with SARS-CoV-2.
Li JX, Zhu FC. Lancet Infect Dis. 2022 Jul;22(7):916-917. doi: 10.1016/S1473-3099(22)00162-1. Epub 2022 Apr 18. PMID: 35447084

Hansen's disease and **COVID-19** co-infection in Brazil.
Repsold TAR, Collin SM, Bouth RC, Cerqueira SRPS, Brezinscki MS, Peixoto RRGB, Fonseca AMFA, Peixoto MLDS, Rabelo Mendes S, Gomes CM, Salgado CG, Deps PD. Int J Dermatol. 2022 Jul 1. doi: 10.1111/ijd.16319. Online ahead of print. PMID: 35775153

**COVID-19 Vaccine** Hesitancy: A Critical Time Period Analysis.
Kues JR, Knapke JM, Elshaer S, Mendell AM, Hildreth L, Schuckman SM, Wijesooriya J, Butsch Kovacic M. Int J Environ Res Public Health. 2022 Jul 1;19(13):8098. doi: 10.3390/ijerph19138098. PMID: 35805757

**COVID-19 vaccine** hesitancy and patient self-advocacy: a statistical analysis of those who can and can't get vaccinated.
Ashwell D, Cullinane J, Croucher SM. BMC Public Health. 2022 Jul 5;22(1):1296. doi: 10.1186/s12889-022-13661-4. PMID: 35790942

Myopericarditis following **COVID-19** vaccination and non-**COVID-19** vaccination: a systematic review and meta-analysis.
Ling RR, Ramanathan K, Tan FL, Tai BC, Somani J, Fisher D, MacLaren G. Lancet Respir Med. 2022 Jul;10(7):679-688. doi: 10.1016/S2213-2600(22)00059-5. Epub 2022 Apr 11. PMID: 35421376

**COVID-19** Challenge: A Quest for Effective **Vaccine** Strategies Against Circulating and Emerging SARS-CoV-2 Variants.
Yogesh R, Srivastava N, Abbas Bukhari SN. Curr Pharm Des. 2022 Jul 1. doi: 10.2174/1381612828666220701160116. Online ahead of print. PMID: 35786330

Nucleocapsid as a Next Generation **COVID-19 Vaccine** Candidate.
Oronsky B, Larson C, Caroen S, Hedjran F, Sanchez A, Prokopenko E, Reid T. Int J Infect Dis. 2022 Jul 1:S1201-9712(22)00379-4. doi: 10.1016/j.ijid.2022.06.046. Online ahead of print. PMID: 35788417

Estimates of **COVID-19 vaccine** uptake in major occupational groups and detailed occupational categories in the United States, April-May 2021.
Henneberger PK, Cox-Ganser JM, Guthrie GM, Groth CP. Am J Ind Med. 2022 Jul;65(7):525-536. doi: 10.1002/ajim.23370. Epub 2022 May 19. PMID: 35587657

Communications to Promote Interest and Confidence in **COVID-19** Vaccines.
Thorpe A, Fagerlin A, Drews FA, Butler J, Stevens V, Riddoch MS, Scherer LD. Am J Health Promot. 2022 Jul;36(6):976-986. doi: 10.1177/08901171221082904. Epub 2022 Apr 12. PMID: 35411819

The impact of **COVID-19 vaccine** on sperm quality.
Barda S, Laskov I, Grisaru D, Lehavi O, Kleiman S, Wenkert A, Azem F, Hauser R, Michaan N. Int J Gynaecol Obstet. 2022 Jul;158(1):116-120. doi: 10.1002/ijgo.14135. Epub 2022 Feb 26. PMID: 35128663

Impact of **COVID-19 Vaccine** Misinformation on Social Media Virality: Content Analysis of Message Themes and Writing Strategies.
Ngai CSB, Singh RG, Yao L. J Med Internet Res. 2022 Jul 6;24(7):e37806. doi: 10.2196/37806. PMID: 35731969

Safety and immunogenicity of mRNA-LNP **COVID-19 vaccine** CVnCoV in Latin American adults: A phase 2 randomized study.
Sáez-Llorens X, Lanata C, Aranguren E, Celis CR, Cornejo R, DeAntonio R, Ecker L, Garrido D, Gil AI, Gonzales M, Hess-Holtz M, Leroux-Roels G, Junker H, Kays SK, Koch SD, Lazzaro S, Mann P, Quintini G, Srivastava B, Vahrenhorst D, von Eisenhart-Rothe P, Wolz OO, Oostvogels L. Vaccine X. 2022 Aug;11:100189. doi: 10.1016/j.jvacx.2022.100189. Epub 2022 Jul 1. PMID: 35791320

Comparing Reactogenicity of **COVID-19** vaccines: a systematic review and meta-analysis.
Sutton N, San Francisco Ramos A, Beales E, Smith D, Ikram S, Galiza E, Hsia Y, Heath PT. Expert Rev Vaccines. 2022 Jul 7. doi: 10.1080/14760584.2022.2098719. Online ahead of print. PMID: 35796029

What determines health professionals' **COVID-19 vaccine** hesitancy? A nationwide study.
Estrela M, Magalhães Silva T, Roque V, Rebelo Gomes E, Roque F, Herdeiro MT, Figueiras A. Eur J Clin Invest. 2022 Jul;52(7):e13785. doi: 10.1111/eci.13785. Epub 2022 Apr 8. PMID: 35363886

Characteristics and perceptions associated with **COVID-19** vaccination hesitancy among pregnant and postpartum individuals: A cross-sectional study.
Kiefer MK, Mehl R, Costantine MM, Johnson A, Cohen J, Summerfield TL, Landon MB, Rood KM, Venkatesh KK. BJOG. 2022 Jul;129(8):1342-1351. doi: 10.1111/1471-0528.17110. Epub 2022 Feb 16. PMID: 35104382

Intention to Receive a **COVID-19 Vaccine** by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada.
Kaida A, Brotto LA, Murray MCM, Côté HCF, Albert AY, Nicholson V, Gormley R, Gordon S, Booth A, Smith LW, Baaske A, Galea LAM, Sadarangani M, Ogilvie GS. AIDS Behav. 2022 Jul;26(7):2242-2255. doi: 10.1007/s10461-022-03577-w. Epub 2022 Jan 12. PMID: 35020094

**COVID-19 vaccine** waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE **COVID** Study.
Menni C, May A, Polidori L, Louca P, Wolf J, Capdevila J, Hu C, Ourselin S, Steves CJ, Valdes AM, Spector TD. Lancet Infect Dis. 2022 Jul;22(7):1002-1010. doi: 10.1016/S1473-3099(22)00146-3. Epub 2022 Apr 8. PMID: 35405090

Adverse reactions to the first and second doses of Pfizer-BioNTech **COVID-19 vaccine** among healthcare workers.
Maruyama A, Sawa T, Teramukai S, Katoh N. J Infect Chemother. 2022 Jul;28(7):934-942. doi: 10.1016/j.jiac.2022.03.015. Epub 2022 Mar 25. PMID: 35361536

Prevalence of Previous **COVID-19** Infection, **COVID-19** Vaccination Receipt, and Intent to Vaccinate Among the US Workforce.
Nguyen KH, Irvine S, Chung M, Yue H, Sheetoh C, Chui K, Allen JD. Public Health Rep. 2022 Jul-Aug;137(4):755-763. doi: 10.1177/00333549221085238. Epub 2022 Apr 9. PMID: 35403489

Humoral and cellular immune memory to four **COVID-19** vaccines.
Zhang Z, Mateus J, Coelho CH, Dan JM, Moderbacher CR, Gálvez RI, Cortes FH, Grifoni A, Tarke A, Chang J, Escarrega EA, Kim C, Goodwin B, Bloom NI, Frazier A, Weiskopf D, Sette A, Crotty S. Cell. 2022 Jul 7;185(14):2434-2451.e17. doi: 10.1016/j.cell.2022.05.022. Epub 2022 May 27. PMID: 35764089

mRNA-based **COVID-19** Vaccines Booster Dose: Benefits, Risks and Coverage.
Nashwan A, Yassin M, Soliman A, Desanctis V, Ibrahim M. Acta Biomed. 2022 Jul 1;93(3):e2022236. doi: 10.23750/abm.v93i3.13103. PMID: 35775753

Revisiting **COVID-19 vaccine** hesitancy around the world using data from 23 countries in 2021.
Lazarus JV, Wyka K, White TM, Picchio CA, Rabin K, Ratzan SC, Parsons Leigh J, Hu J, El-Mohandes A. Nat Commun. 2022 Jul 1;13(1):3801. doi: 10.1038/s41467-022-31441-x. PMID: 35778396

Bilateral facial palsy after **COVID-19** vaccination.
Andreozzi V, D'arco B, Pagliano P, Toriello A, Barone P. Neurol Sci. 2022 Jul;43(7):4069-4079. doi: 10.1007/s10072-022-05982-4. Epub 2022 Apr 1. PMID: 35364768

Immune response and safety to inactivated **COVID-19 vaccine**: a comparison between people living with HIV and HIV-naive individuals.
Zou S, Wu M, Ming F, Wu S, Guo W, Marley G, Xing Z, Zhang Z, Zeng M, Sun C, Zhang J, Tang W, Liang K. AIDS Res Ther. 2022 Jul 5;19(1):33. doi: 10.1186/s12981-022-00459-y. PMID: 35791004

Immunoassay and mass cytometry revealed immunological profiles induced by inactivated BBIBP **COVID-19 vaccine**.

Cheng ZJ, Huang H, Liu Q, Zhong R, Liang Z, Xue M, Liu M, Li S, Wang H, Zheng P, Zheng C, Sun B. J Med Virol. 2022 Jul 8. doi: 10.1002/jmv.27983. Online ahead of print. PMID: 35801663

Chatbot-Delivered **COVID-19 Vaccine** Communication Message Preferences of Young Adults and Public Health Workers in Urban American Communities: Qualitative Study.
Weeks R, Cooper L, Sangha P, Sedoc J, White S, Toledo A, Gretz S, Lahav D, Martin N, Michel A, Lee JH, Slonim N, Bar-Zeev N. J Med Internet Res. 2022 Jul 6;24(7):e38418. doi: 10.2196/38418. PMID: 35737898

Allergic Reactions to **COVID-19** Vaccines: Risk Factors, Frequency, Mechanisms and Management.
Luxi N, Giovanazzi A, Arcolaci A, Bonadonna P, Crivellaro MA, Cutroneo PM, Ferrajolo C, Furci F, Guidolin L, Moretti U, Olivieri E, Petrelli G, Zanoni G, Senna G, Trifirò G. BioDrugs. 2022 Jul;36(4):443-458. doi: 10.1007/s40259-022-00536-8. Epub 2022 Jun 13. PMID: 35696066

**COVID-19 vaccine** effectiveness against symptomatic SARS-CoV-2 infection and severe **COVID-19** outcomes from Delta AY.4.2: Cohort and test-negative study of 5.4 million individuals in Scotland.
Kerr S, Vasileiou E, Robertson C, Sheikh A. J Glob Health. 2022 Jul 9;12:05025. doi: 10.7189/jogh.12.05025. PMID: 35802764

**Vaccine** and Psychological Booster: Factors Associated With Older Adults' Compliance to the Booster **COVID-19 Vaccine** in Israel.
Ben-David BM, Keisari S, Palgi Y. J Appl Gerontol. 2022 Jul;41(7):1636-1640. doi: 10.1177/07334648221081982. Epub 2022 Apr 5. PMID: 35379029

Rapid progress in our understanding of **COVID-19 vaccine** allergy: A cause for optimism, not hesitancy.
Banerji A, Norton AE, Blumenthal KG, Stone CA Jr, Phillips E. J Allergy Clin Immunol. 2022 Jul;150(1):12-16. doi: 10.1016/j.jaci.2022.03.023. Epub 2022 Apr 7. PMID: 35398412

**Vaccine**-Related Lymph Nodes: The Emerging Pitfalls of 18F-Fluorocholine and 68Ga-PSMA-11 PET/CT in the Era of **COVID-19** Vaccination.
Ah-Thiane L, Ferrer L, Maucherat B, Fleury V, Le Thiec M, Rusu D, Rousseau C. Clin Nucl Med. 2022 Jul 1;47(7):575-582. doi: 10.1097/RLU.0000000000004190. Epub 2022 Apr 27. PMID: 35675134

Association study between herpes zoster reporting and mRNA **COVID-19** vaccines (BNT162b2 and mRNA-1273).
Préta LH, Contejean A, Salvo F, Treluyer JM, Charlier C, Chouchana L. Br J Clin Pharmacol. 2022 Jul;88(7):3529-3534. doi: 10.1111/bcp.15280. Epub 2022 Feb 28. PMID: 35174524

Anaphylaxis and Related Events Post-**COVID-19** Vaccination: A Systematic Review.
Paul P, Janjua E, AlSubaie M, Ramadorai V, Mushannen B, Vattoth AL, Khan W, Bshesh K, Nauman A, Mohammed I, Bouhali I, Khalid M, Zakaria D. J Clin Pharmacol. 2022 Jul 6. doi: 10.1002/jcph.2120. Online ahead of print. PMID: 35794852

Correlates of the **COVID-19 Vaccine** Hesitancy Among Indians.
Bansal P, Raj A, Sinha RK. Asia Pac J Public Health. 2022 Jul;34(5):583-585. doi: 10.1177/10105395221077065. Epub 2022 Feb 7. PMID: 35130754

Serosurveillance after a **COVID-19 vaccine** campaign in a Swiss police cohort.
Sendi P, Thierstein M, Widmer N, Babongo Bosombo F, Büchi AE, Güntensperger D, Blum MR, Baldan R, Tinguely C, Gahl B, Heg D, Theel ES, Berbari E, Endimiani A, Gowland P, Niederhauser C; PoliCOV-19 study. Immun Inflamm Dis. 2022 Jul;10(7):e640. doi: 10.1002/iid3.640. PMID: 35759237

**COVID-19** vaccination among pregnant people in the United States: a systematic review.
Rawal S, Tackett RL, Stone RH, Young HN. Am J Obstet Gynecol MFM. 2022 Jul;4(4):100616. doi: 10.1016/j.ajogmf.2022.100616. Epub 2022 Mar 10. PMID: 35283351

Exacerbation of immune thrombocytopenia following initial and booster vaccination with Pfizer-BioNTech **COVID-19 vaccine**.
Aharoni M, Leader A, Shochat T, Raanani P, Spectre G. Platelets. 2022 Jul 4;33(5):781-786. doi: 10.1080/09537104.2022.2071856. Epub 2022 May 10. PMID: 35536172

**COVID-19** pandemic vaccination preparedness strategies for independent community pharmacies.
Mercer J, Liang A, Yoon J, Nguyen J, Carroll JC, Coley KC. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1172-1178.e3. doi: 10.1016/j.japh.2022.01.003. Epub 2022 Jan 6. PMID: 35123895

Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech **COVID-19** Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.
Fleming-Dutra KE, Wallace M, Moulia DL, Twentyman E, Roper LE, Hall E, Link-Gelles R, Godfrey M, Woodworth KR, Anderson TC, Rubis AB, Shanley E 3rd, Jones JM, Morgan RL, Brooks O, Talbot HK, Lee GM, Bell BP, Daley M, Meyer S, Oliver SE. MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):859-868. doi: 10.15585/mmwr.mm7126e2. PMID: 35771731

Public Attitudes toward **COVID-19** Vaccinations before Dawn in Japan: Ethics and Future Perspectives.
Nakada H, Takashima K, Maru Y, Ikka T, Yuji K, Yoshida S, Matsui K. Asian Bioeth Rev. 2022 May 11;14(3):287-302. doi: 10.1007/s41649-022-00207-4. eCollection 2022 Jul. PMID: 35573157

**COVID-19 Vaccine** Hesitancy Among Deployed Personnel: Correspondence.
Mungmunpuntipantip R, Wiwanitkit V. Mil Med. 2022 Jul 1;187(7-8):215. doi: 10.1093/milmed/usac042. PMID: 35257161

**COVID-19 Vaccine** Clinic Real-Time Throughput Analysis: Development and Implementation of an Innovative Data Collection Tool.
Skaggs MD, Wendel SK, Zane RD, Resnick-Ault D. J Healthc Qual. 2022 Jul-Aug 01;44(4):201-209. doi: 10.1097/JHQ.0000000000000343. Epub 2022 Mar 28. PMID: 35343922

Conspiracy claims and secret intentions as predictors of psychological coping and **vaccine** uptake during the **COVID-19** pandemic.
Eshel Y, Kimhi S, Marciano H, Adini B. J Psychiatr Res. 2022 Jul;151:311-318. doi: 10.1016/j.jpsychires.2022.04.042. Epub 2022 May 2. PMID: 35526447

Effectiveness and Durability of **COVID-19** Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
Jena A, James D, Singh AK, Dutta U, Sebastian S, Sharma V. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1456-1479.e18. doi: 10.1016/j.cgh.2022.02.030. Epub 2022 Feb 19. PMID: 35189387

**COVID-19** Vaccination Status and Concerns Among People Who Use Drugs in Oregon.
Stack E, Shin S, LaForge K, Pope J, Leichtling G, Larsen JE, Byers M, Leahy JM, Hoover D, Chisholm L, Korthuis PT. J Addict Med. 2022 Jul 7. doi: 10.1097/ADM.0000000000001002. Online ahead of print. PMID: 35797436

Social cohesion and loneliness are associated with the antibody response to **COVID-19** vaccination.
Stephen G, Siobhán H, Muldoon OT, Whittaker AC. Brain Behav Immun. 2022 Jul;103:179-185. doi: 10.1016/j.bbi.2022.04.017. Epub 2022 Apr 22. PMID: 35470012

Recurrent Myocarditis Following **COVID-19** Infection and the mRNA **Vaccine**.
Pasha MA, Isaac S, Khan Z. Cureus. 2022 Jul 7;14(7):e26650. doi: 10.7759/cureus.26650. eCollection 2022 Jul. PMID: 35815297

The role of mild and asymptomatic infections on **COVID-19** vaccines performance: A modeling study.
Aguiar M, Van-Dierdonck JB, Mar J, Stollenwerk N. J Adv Res. 2022 Jul;39:157-166. doi: 10.1016/j.jare.2021.10.012. Epub 2021 Nov 16. PMID: 35777906

Short and mid-term SARS-CoV-2 antibody response after inactivated **COVID-19 vaccine** in hemodialysis and kidney transplant patients.
Dheir H, Tocoglu A, Toptan H, Pinar M, Demirci T, Koroglu M, Yaylaci S, Genc AB, Genc AC, Firat N, Karabay O, Sipahi S. J Med Virol. 2022 Jul;94(7):3176-3183. doi: 10.1002/jmv.27714. Epub 2022 Mar 22. PMID: 35277975

**COVID-19 vaccine** campaign has now opened up for children aged 5-11. How are kids going to live it?
Dobrina R, Bicego L. J Pediatr Nurs. 2022 Jul-Aug;65:e19. doi: 10.1016/j.pedn.2021.12.020. Epub 2022 Jan 7. PMID: 35012869

Patients' Perspectives on Emergency Department **COVID-19** Vaccination and Vaccination Messaging Through Randomized Vignettes.
Waxman MJ, Ray M, Schechter-Perkins EM, Faryar K, Flynn KC, Breen M, Wojcik SM, Berry F, Zheng A, Ata A, Lerner EB, Lyons MS, McGinnis S. Public Health Rep. 2022 Jul-Aug;137(4):774-781. doi: 10.1177/00333549221085580. Epub 2022 Apr 23. PMID: 35465764

Long-term evolution of humoral immune response after SARS-CoV-2 infection.
Teyssou E, Zafilaza K, Sayon S, Marot S, Dropy M, Soulie C, Abdi B, Tubach F, Hausfater P, Marcelin AG, Boutolleau D; SEROCOV study group. Clin Microbiol Infect. 2022 Jul;28(7):1027.e1-1027.e4. doi: 10.1016/j.cmi.2022.03.012. Epub 2022 Mar 17. PMID: 35307573

Safety of inactivated **COVID-19 vaccine** in tuberous sclerosis complex patients with epilepsy treated with rapamycin.
Lu Q, Wang YY, Wang QH, Tang LN, Yang XY, Dun S, Zou LP. Seizure. 2022 Jul;99:71-74. doi: 10.1016/j.seizure.2022.05.010. Epub 2022 May 16. PMID: 35605444

Patient Perspectives on the **COVID-19 Vaccine**: A Pilot Survey Study of Patients in Endocrinology Clinics.
Mikkilineni P, Simon R, Bhan A, Rao SD. Endocr Pract. 2022 Jul 1:S1530-891X(22)00545-6. doi: 10.1016/j.eprac.2022.06.010. Online ahead of print. PMID: 35787467

Parental **COVID-19 Vaccine** Hesitancy in Diverse Communities: A National Survey.
Maurice AS, Block R, Sanchez G, Szilagyi PG. Acad Pediatr. 2022 Jul 5:S1876-2859(22)00309-6. doi: 10.1016/j.acap.2022.06.016. Online ahead of print. PMID: 35803490

Association of BNT162b2 **Vaccine** Third Dose Receipt With Incidence of SARS-CoV-2 Infection, **COVID-19**-Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021.
Muhsen K, Maimon N, Mizrahi AY, Varticovschi B, Bodenheimer O, Cohen D, Dagan R. JAMA Netw Open. 2022 Jul 1;5(7):e2219940. doi: 10.1001/jamanetworkopen.2022.19940. PMID: 35796153

**COVID-19 vaccine** distribution planning using a congested queuing system-A real case from Australia.
Jahani H, Chaleshtori AE, Khaksar SMS, Aghaie A, Sheu JB. Transp Res E Logist Transp Rev. 2022 Jul;163:102749. doi: 10.1016/j.tre.2022.102749. Epub 2022 May 30. PMID: 35664528

The Promises of Speeding Up: Changes in Requirements for Animal Studies and Alternatives during **COVID-19 Vaccine** Approval-A Case Study.
Ritskes-Hoitinga M, Barella Y, Kleinhout-Vliek T. Animals (Basel). 2022 Jul 5;12(13):1735. doi: 10.3390/ani12131735. PMID: 35804634

Oncologist counseling practice and **COVID-19** vaccination outcomes for patients with history of PEG-asparaginase hypersensitivity.
Zarnegar-Lumley S, Stone CA Jr, Smith CM, Hall LL, Luck KE, Koo G, Plager JH, Phillips EJ, Friedman DL. Pediatr Blood Cancer. 2022 Jul;69(7):e29686. doi: 10.1002/pbc.29686. Epub 2022 Mar 30. PMID: 35353440

Childhood **COVID-19 vaccine** acceptance and preference from caregivers and healthcare workers in China: A survey experiment.
Hou Z, Song K, Wang Q, Zang S, Tu S, Chantler T, Larson HJ. Prev Med. 2022 Jul 6:107138. doi: 10.1016/j.ypmed.2022.107138. Online ahead of print. PMID: 35809825

Parents' perceptions on **COVID-19** vaccination as the new routine for their children ≤ 11 years old.
Humble RM, Sell H, Wilson S, Sadarangani M, Bettinger JA, Meyer SB, Dubé È, Lemaire-Paquette S, Gagneur A, MacDonald SE. Prev Med. 2022 Jul 2;161:107125. doi: 10.1016/j.ypmed.2022.107125. Online ahead of print. PMID: 35792197

Immune response and reactogenicity after immunization with two-doses of an experimental **COVID-19 vaccine** (CVnCOV) followed by a third-fourth shot with a standard mRNA **vaccine** (BNT162b2): RescueVacs multicenter cohort study.
Ascaso-Del-Rio A, García-Pérez J, Pérez-Olmeda M, Arana-Arri E, Vergara I, Pérez-Ingidua C, Bermejo M, Castillo de la Osa M, Imaz-Ayo N, Riaño Fernández I, Astasio González O, Díez-Fuertes F, Meijide S, Arrizabalaga J, Hernández Gutiérrez L, de la Torre-Tarazona HE, Mariano Lázaro A, Vargas-Castrillón E, Alcamí J, Portolés A; RescueVac study Group. EClinicalMedicine. 2022 Jul 1;51:101542. doi: 10.1016/j.eclinm.2022.101542. eCollection 2022 Sep. PMID: 35795398

Experience with polyethylene glycol allergy-guided risk management for **COVID-19 vaccine** anaphylaxis.
Brockow K, Mathes S, Fischer J, Volc S, Darsow U, Eberlein B, Biedermann T. Allergy. 2022 Jul;77(7):2200-2210. doi: 10.1111/all.15183. Epub 2021 Dec 4. PMID: 34806775

Facilitators and barriers to **COVID-19** vaccination uptake among ethnic minorities: A qualitative study in primary care.
Magee L, Knights F, Mckechnie DGJ, Al-Bedaery R, Razai MS. PLoS One. 2022 Jul 8;17(7):e0270504. doi: 10.1371/journal.pone.0270504. eCollection 2022. PMID: 35802738

Ultrasound Features to Differentiate **COVID-19 Vaccine**-Induced Benign Adenopathy from Breast Cancer Related Malignant Adenopathy.
Hl C, Gj W, Jwt L, J S, Lp M, Ht LP. Acad Radiol. 2022 Jul;29(7):1004-1012. doi: 10.1016/j.acra.2022.02.015. Epub 2022 Feb 21. PMID: 35296413

Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based **COVID-19 vaccine** elicits potent humoral and cellular immune responses in mice.
Li X, Wang L, Liu J, Fang E, Liu X, Peng Q, Zhang Z, Li M, Liu X, Wu X, Zhao D, Yang L, Li J, Cao S, Huang Y, Shi L, Xu H, Wang Y, Suo Y, Yue G, Nie J, Huang W, Li W, Li Y. Emerg Microbes Infect. 2022 Jul 1:1-27. doi: 10.1080/22221751.2022.2097479. Online ahead of print. PMID: 35775819

Implications of **COVID-19 vaccine** effectiveness waning for public health.
Odone A, Vigezzi GP, Baldanti F. Lancet Infect Dis. 2022 Jul;22(7):918-919. doi: 10.1016/S1473-3099(22)00233-X. Epub 2022 Apr 22. PMID: 35468334

Rural community pharmacists' ability and interest in administering **COVID-19** vaccines in the Southern United States.
Carpenter DM, Hastings T, Westrick S, Mashburn P, Rosenthal M, Smith M, Kiser S, Gamble A, Brewer NT, Curran G. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1379-1383. doi: 10.1016/j.japh.2022.01.013. Epub 2022 Jan 19. PMID: 35221234

A community-based study in the central district of Giresun: **COVID-19 vaccine** hesitancy.
Ata Teneler A, Ayhan F, Zaim E, Ozek U. Hum Vaccin Immunother. 2022 Jul 7:2092362. doi: 10.1080/21645515.2022.2092362. Online ahead of print. PMID: 35797599

Telemedicine in Neurosurgery During the **COVID-19** Outbreak: Where We Are 1 Year Later.
Mouchtouris N, Yu S, Prashant G, Nelson N, Reyes M, Gonzalez G, Smit R, Collopy S, Jabbour P, Sharan A, Harrop J, Rosenwasser R, Evans JJ. World Neurosurg. 2022 Jul;163:e83-e88. doi: 10.1016/j.wneu.2022.03.037. Epub 2022 Mar 16. PMID: 35306198

**COVID-19 vaccine** acceptability among people in Australia who inject drugs: Update from the 2021 Illicit Drug Reporting System interviews.
Price O, Dietze PM, Maher L, Crawford S, Peacock A. Drug Alcohol Rev. 2022 Jul;41(5):1025-1028. doi: 10.1111/dar.13448. Epub 2022 Feb 20. PMID: 35184346

High But Inequitable **COVID-19 Vaccine** Uptake Among Patients with Inflammatory Bowel Disease.
Schell TL, Richard LJ, Tippins K, Russ RK, Hayney MS, Caldera F. Clin Gastroenterol Hepatol. 2022 Jul;20(7):1606-1608.e2. doi: 10.1016/j.cgh.2021.12.013. Epub 2021 Dec 9. PMID: 34896281

Delayed Access to **COVID-19** Vaccines: A Perspective on Low-income Countries in Africa.
Hassan MA, Aliyu S. Int J Health Serv. 2022 Jul;52(3):323-329. doi: 10.1177/00207314221096365. Epub 2022 Apr 26. PMID: 35469499

**COVID-19 Vaccine** Hesitancy and Interpersonal Trust: Correspondence.
Kleebayoon A, Wiwanitkit V, Sookaromdee P. Asia Pac J Public Health. 2022 Jul 9:10105395221110455. doi: 10.1177/10105395221110455. Online ahead of print. PMID: 35815578

Describing the population experiencing **COVID-19 vaccine** breakthrough following second vaccination in England: a cohort study from OpenSAFELY.
OpenSAFELY Collaborative, Green A, Curtis H, Hulme W, Williamson E, McDonald H, Bhaskaran K, Rentsch C, Schultze A, MacKenna B, Mahalingasivam V, Tomlinson L, Walker A, Fisher L, Massey J, Andrews C, Hopcroft L, Morton C, Croker R, Morley J, Mehrkar A, Bacon S, Evans D, Inglesby P, Hickman G, Ward T, Davy S, Mathur R, Tazare J, Eggo R, Wing K, Wong A, Forbes H, Bates C, Cockburn J, Parry J, Hester F, Harper S, Douglas I, Evans S, Smeeth L, Goldacre B. BMC Med. 2022 Jul 5;20(1):243. doi: 10.1186/s12916-022-02422-0. PMID: 35791013 F

**COVID-19 vaccine** uptake among patients with systemic lupus erythematosus in the American Midwest: The Lupus Midwest Network (LUMEN).
Chevet B, Figueroa-Parra G, Yang JX, Hulshizer CA, Gunderson TM, Duong SQ, Putman MS, Barbour KE, Crowson CS, Duarte-García A. J Rheumatol. 2022 Jul 1:jrheum.220220. doi: 10.3899/jrheum.220220. Online ahead of print. PMID: 35777817

Secondary Syphilis Presentation and Urticarial Eruption After Moderna **COVID-19** Vaccination.
Brockshus A, Evans MO, Punch C. Mil Med. 2022 Jul 2:usac191. doi: 10.1093/milmed/usac191. Online ahead of print. PMID: 35778833

Vaccination approval literacy and its effects on intention to receive future **COVID-19** immunization.
Carmosino E, Ruisinger JF, Kinsey JD, Melton BL. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1374-1378.e2. doi: 10.1016/j.japh.2022.01.001. Epub 2022 Jan 6. PMID: 35065886

Immunity waning after **COVID vaccine** booster *vs.* infection-better than expected.
Khoury J, Najjar-Debbiny R, Elemy A, Jabbour A, Haj J, Abu-Sini M, Yasin R, Amin M, Hellou E, Nasrallah N, Saffouri A, Hakim F. Infect Dis (Lond). 2022 Jul 7:1-4. doi: 10.1080/23744235.2022.2097304. Online ahead of print. PMID: 35796285

A data-driven robust optimization model by cutting hyperplanes on **vaccine** access uncertainty in **COVID-19 vaccine** supply chain.
Gilani H, Sahebi H. Omega. 2022 Jul;110:102637. doi: 10.1016/j.omega.2022.102637. Epub 2022 Mar 11. PMID: 35291647

Axillary lymphangioma that developed following **COVID-19** vaccination: a case report.
Sasa S, Inoue H, Inui T, Miyamoto N, Aoyama M, Okumura K, Toba H, Yoshida T, Tezuka M, Hirose C, Saijo Y, Uehara H, Izumori A, Takahashi M, Sasa M, Takizawa H. Surg Case Rep. 2022 Jul 8;8(1):131. doi: 10.1186/s40792-022-01488-5. PMID: 35798903

Inadvertent injection of **COVID-19 vaccine** into deltoid muscle vasculature may result in **vaccine** distribution to distance tissues and consequent adverse reactions.
Merchant H. Postgrad Med J. 2022 Jul;98(1161):e5. doi: 10.1136/postgradmedj-2021-141119. Epub 2021 Sep 29. PMID: 34588294

Guillain-Barré Syndrome Associated with **COVID-19** Vaccines: A Perspective From Spontaneous Report Data.
Atzenhoffer M, Auffret M, Pegat A, Masmoudi K, Khouri C, Bertin B, Vial T. Clin Drug Investig. 2022 Jul;42(7):581-592. doi: 10.1007/s40261-022-01164-4. Epub 2022 Jun 9. PMID: 35676452

Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.
Taquet M, Dercon Q, Harrison PJ. Brain Behav Immun. 2022 Jul;103:154-162. doi: 10.1016/j.bbi.2022.04.013. Epub 2022 Apr 18. PMID: 35447302

Public attitude toward **Covid-19** vaccination: The influence of education, partisanship, biological literacy, and coronavirus understanding.
Miller JD, Ackerman MS, Laspra B, Polino C, Huffaker JS. FASEB J. 2022 Jul;36(7):e22382. doi: 10.1096/fj.202200730. PMID: 35657606

**COVID-19 vaccine** effectiveness against the omicron (BA.2) variant in England.
Kirsebom FCM, Andrews N, Stowe J, Toffa S, Sachdeva R, Gallagher E, Groves N, O'Connell AM, Chand M, Ramsay M, Bernal JL. Lancet Infect Dis. 2022 Jul;22(7):931-933. doi: 10.1016/S1473-3099(22)00309-7. Epub 2022 May 24. PMID: 35623379

Perceptions of **COVID-19** vaccines in a predominantly Hispanic patient population from the Texas-Mexico border.
Amundson CJ, Sias JJ, Frietze GA. J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4S):S17-S21.e2. doi: 10.1016/j.japh.2021.11.003. Epub 2021 Nov 5. PMID: 34862142

Follow-up cardiac magnetic resonance in children with **vaccine**-associated myocarditis.
Hadley SM, Prakash A, Baker AL, de Ferranti SD, Newburger JW, Friedman KG, Dionne A. Eur J Pediatr. 2022 Jul;181(7):2879-2883. doi: 10.1007/s00431-022-04482-z. Epub 2022 Apr 28. PMID: 35482094

**COVID-19 Vaccine** Acceptance and Hesitancy among Health Care Workers (HCWs) In Two Major Urban Centers in Khyber-Pakhtunkhwa, Pakistan.
Khan S, Uddin A, Imran M, Ali Y, Khan S, Salman Khan M, Trutter B, Asfandiyar M, Iqbal Z. Asia Pac J Public Health. 2022 Jul;34(5):580-582. doi: 10.1177/10105395221083382. Epub 2022 Mar 10. PMID: 35264019

A Fourth Dose of **COVID-19 Vaccine** Does Not Induce Neutralization of the Omicron Variant Among Solid Organ Transplant Recipients With Suboptimal **Vaccine** Response.
Karaba AH, Johnston TS, Aytenfisu TY, Akinde O, Eby Y, Ruff JE, Abedon AT, Alejo JL, Blankson JN, Cox AL, Bailey JR, Klein SL, Pekosz A, Segev DL, Tobian AAR, Werbel WA. Transplantation. 2022 Jul 1;106(7):1440-1444. doi: 10.1097/TP.0000000000004140. Epub 2022 Apr 4. PMID: 35417115

A comparison of seasonal influenza and novel **Covid-19 vaccine** intentions: A cross-sectional survey of **vaccine** hesitant adults in England during the 2020 pandemic.
Antonopoulou V, Goffe L, Meyer CJ, Grimani A, Graham F, Lecouturier J, Tang MY, Chadwick P, Sniehotta FF. Hum Vaccin Immunother. 2022 Jul 11:2085461. doi: 10.1080/21645515.2022.2085461. Online ahead of print. PMID: 35816683

Early Efficacy and Safety of the Third Dose Inactivated **COVID-19 Vaccine** Among People Living With HIV.
Tan Y, Zou S, Ming F, Zhang Z, Xing Z, Wu S, Guo W, Tang W, Liang K. J Acquir Immune Defic Syndr. 2022 Jul 1;90(3):e1-e3. doi: 10.1097/QAI.0000000000002953. PMID: 35298450

Social and Behavioral Factors Associated with Lack of Intent to Receive **COVID-19 Vaccine**, Japan.
Arashiro T, Arima Y, Stucky A, Smith C, Hibberd M, Ariyoshi K, Suzuki M. Emerg Infect Dis. 2022 Jul 6;28(9). doi: 10.3201/eid2809.220300. Online ahead of print. PMID: 35793812

Socio-economic and behavioral characteristics associated with **COVID-19 vaccine** hesitancy under a declared state of emergency in Japan.
Suzuki N, Yamamoto T, Uchiumi C, Sugaya N. Brain Behav Immun Health. 2022 Jul;22:100448. doi: 10.1016/j.bbih.2022.100448. Epub 2022 Mar 23. PMID: 35345671

Active monitoring of adverse reactions following **COVID-19** and other vaccinations: a feasibility study as part of the CoVaKo project.
Zeschick N, Warkentin L, Kühlein T, Steininger P, Überla K, Hueber S, Sebastião M. Pilot Feasibility Stud. 2022 Jul 2;8(1):134. doi: 10.1186/s40814-022-01088-y. PMID: 35780172

Fixed drug eruption after Pfizer-BioNTech **COVID-19 vaccine**: A case report.
Lellig E, Mouton-Faivre C, Abs D, Bursztejn AC. J Allergy Clin Immunol Pract. 2022 Jul;10(7):1922-1923. doi: 10.1016/j.jaip.2022.03.033. Epub 2022 Apr 22. PMID: 35470099

Ethnic Minorities' Perceptions of **COVID-19** Vaccines and Challenges in the Pandemic: A Qualitative Study to Inform **COVID-19** Prevention Interventions.
Zhou S, Villalobos JP, Munoz A, Bull S. Health Commun. 2022 Jul 1:1-12. doi: 10.1080/10410236.2022.2093557. Online ahead of print. PMID: 35775369

Acute cervical dystonia following the BNT162b2 mRNA **COVID-19 vaccine**.
Algahtani HA, Shirah BH, Alwafi E. Clin Neurol Neurosurg. 2022 Jul;218:107304. doi: 10.1016/j.clineuro.2022.107304. Epub 2022 May 19. PMID: 35605509

Disparities in the offer of **COVID-19** vaccination to migrants and non-migrants in Norway: a cross sectional survey study.
Diaz E, Dimka J, Mamelund SE. BMC Public Health. 2022 Jul 4;22(1):1288. doi: 10.1186/s12889-022-13687-8. PMID: 35788219

Self-reported health behaviors and risk perceptions following the **COVID-19** vaccination rollout in the USA: an online survey study.
Thorpe A, Fagerlin A, Drews FA, Shoemaker H, Scherer LD. Public Health. 2022 Jul;208:68-71. doi: 10.1016/j.puhe.2022.05.007. Epub 2022 May 18. PMID: 35717747

Immunogenicity of a third dose of inactivated **COVID-19 vaccine** in people living with HIV-1, HBV, and tuberculosis during the Omicron variant epidemic: a cross-sectional study.
Yan Y, Davgadorj C, Lyu C, Zhang S, Qiu Y. J Infect. 2022 Jul 5:S0163-4453(22)00407-8. doi: 10.1016/j.jinf.2022.06.032. Online ahead of print. PMID: 35803384

Willingness to receive an annual **COVID-19** booster **vaccine** in the German-speaking D-A-CH region in Europe: A cross-sectional study.
Weitzer J, Birmann BM, Steffelbauer I, Bertau M, Zenk L, Caniglia G, Laubichler MD, Steiner G, Schernhammer ES. Lancet Reg Health Eur. 2022 May 29;18:100414. doi: 10.1016/j.lanepe.2022.100414. eCollection 2022 Jul. PMID: 35651957

Acute myocarditis after a third dose of the BNT162b2 **COVID-19 vaccine**.
Fosch X, Serra J, Torres PL, Preda L, González R, Mojer F. Rev Esp Cardiol (Engl Ed). 2022 Jul;75(7):614-616. doi: 10.1016/j.rec.2022.01.009. Epub 2022 Feb 21. PMID: 35277352

Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable **COVID-19 vaccine**.
Wang Z, Popowski KD, Zhu D, de Juan Abad BL, Wang X, Liu M, Lutz H, De Naeyer N, DeMarco CT, Denny TN, Dinh PC, Li Z, Cheng K. Nat Biomed Eng. 2022 Jul 4. doi: 10.1038/s41551-022-00902-5. Online ahead of print. PMID: 35788687

A case of encephalitis following **COVID-19 vaccine**.
Kobayashi Y, Karasawa S, Ohashi N, Yamamoto K. J Infect Chemother. 2022 Jul;28(7):975-977. doi: 10.1016/j.jiac.2022.02.009. Epub 2022 Feb 17. PMID: 35190257

Sudden sensorineural hearing loss with intralabyrinthine hemorrhage after **COVID-19** vaccination.
Jeong J, Yoon PH. Hum Vaccin Immunother. 2022 Jul 6:2097462. doi: 10.1080/21645515.2022.2097462. Online ahead of print. PMID: 35793501

**Vaccine**-Related adverse events following AZD1222 (ChAdOx1-nCoV-**19**) **Covid-19 vaccine** in solid malignancy patients receiving cancer treatment, as compared to age-matched healthy controls.
Pakvisal N, Sainamthip P, Teeyapun N, Luangdilok S, Wanlapakorn N, Yorsaeng R, Poovorawan Y, Pakvisal P, Susiriwatananont T, Zungsontiporn N, Sriuranpong V, Tanasanvimon S, Wanchaijiraboon P. Hum Vaccin Immunother. 2022 Jul 1:2094149. doi: 10.1080/21645515.2022.2094149. Online ahead of print. PMID: 35776836

Exploring the Effects of the **COVID-19** Pandemic on the Children and Families Cared for by Pediatric-Focused Advanced Practice Registered Nurses.
Crawford D, Van Cleve S, McCarthy AM, Kimm V, Nielsen AK, Lee J. J Pediatr Health Care. 2022 Jul-Aug;36(4):321-329. doi: 10.1016/j.pedhc.2022.01.003. Epub 2022 Jan 24. PMID: 35153108

Immunogenicity against the BNT162b2 mRNA **COVID-19 Vaccine** in Rheumatic Disease Patients Receiving Immunosuppressive Therapy.
Sugihara K, Wakiya R, Shimada H, Kameda T, Nakashima S, Kato M, Miyagi T, Mizusaki M, Mino R, Nomura Y, Inoo M, Kadowaki N, Dobashi H. Intern Med. 2022 Jul 1;61(13):1953-1958. doi: 10.2169/internalmedicine.9223-21. Epub 2022 Apr 23. PMID: 35466168

Interpersonal Trust Matters: Factors Associated With **COVID-19 Vaccine** Hesitancy in South Korea.
Jang SH. Asia Pac J Public Health. 2022 Jul;34(5):600-602. doi: 10.1177/10105395221100805. Epub 2022 May 20. PMID: 35596572

Reasons for Individuals' **COVID-19 vaccine** hesitations and changing decisions over time: A longitudinal qualitative study.
Yıldırım DF, Serçekuş P, Özkan S. Vacunas. 2022 Jul 4. doi: 10.1016/j.vacun.2022.06.006. Online ahead of print. PMID: 35813990

Addressing **COVID-19** vaccination equity for Hispanic/Latino communities by attending to aguantarismo: A Californian US-Mexico border perspective.
Sobo EJ, Cervantes G, Ceballos DA, McDaniels-Davidson C. Soc Sci Med. 2022 Jul;305:115096. doi: 10.1016/j.socscimed.2022.115096. Epub 2022 Jun 1. PMID: 35691209

Third trimester messenger RNA **COVID-19** booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth.
Kugelman N, Nahshon C, Shaked-Mishan P, Cohen N, Lahav Sher M, Barsha H, Shalabna E, Zolotarevsky A, Lavie O, Kedar R, Riskin-Mashiah S. Eur J Obstet Gynecol Reprod Biol. 2022 Jul;274:148-154. doi: 10.1016/j.ejogrb.2022.05.029. Epub 2022 May 30. PMID: 35653903

Autoimmune Hepatitis Triggered by **COVID-19 Vaccine**: The First Case From Inactivated **Vaccine**.
Mekritthikrai K, Jaru-Ampornpan P, Komolmit P, Thanapirom K. ACG Case Rep J. 2022 Jul 1;9(7):e00811. doi: 10.14309/crj.0000000000000811. eCollection 2022 Jul. PMID: 35784513

Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) **COVID-19** vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
Smolenov I, Han HH, Li P, Baccarini C, Verhoeven C, Rockhold F, Clemens SAC, Ambrosino D, Richmond P, Siber G, Liang J, Clemens R; SPECTRA Study Group. Lancet Infect Dis. 2022 Jul;22(7):990-1001. doi: 10.1016/S1473-3099(22)00144-X. Epub 2022 Apr 18. PMID: 35447085

**COVID-19 vaccine** perceptions among South Asian communities in the UK: An application of the theory of planned behavior.
Akbar MB, Singh L, Deshpande S, Amoncar N. Health Mark Q. 2022 Jul 5:1-18. doi: 10.1080/07359683.2022.2092325. Online ahead of print. PMID: 35787243

Emergence of Omicron BA.1 and BA.2 variants and concern over **vaccine** breakthrough infection.
Sukaina M, Hasan MM, Essar MY. Ann Med Surg (Lond). 2022 Jul;79:103941. doi: 10.1016/j.amsu.2022.103941. Epub 2022 Jun 6. PMID: 35692969

Refractory immune TTP following Pfizer-BioNTech **COVID-19 vaccine** successfully salvaged with caplacizumab.
Laverdure E, Sperlich C, Fox S. J Thromb Haemost. 2022 Jul;20(7):1696-1698. doi: 10.1111/jth.15751. Epub 2022 May 18. PMID: 35510743

How important are **COVID-19 vaccine** responses in patients with MS on disease-modifying therapies?
Giovannoni G. Mult Scler Relat Disord. 2022 Jul;63:103803. doi: 10.1016/j.msard.2022.103803. Epub 2022 Apr 11. PMID: 35487035

Variations in **COVID-19** vaccination uptake among people in receipt of psychotropic drugs: cross-sectional analysis of a national population-based prospective cohort.

Murphy S, O'Reilly D, Owen RK, Akbari A, Lowthian E, Bedston S, Torabi F, Beggs J, Chuter A, de Lusignan S, Hobbs R, Robertson C, Katikireddi SV, Sheikh A, Bradley DT. Br J Psychiatry. 2022 Jul;221(1):417-424. doi: 10.1192/bjp.2022.36. PMID: 35249568

mRNA **COVID-19 vaccine** effectiveness against SARS-CoV-2 infection in a prospective community cohort, rural Wisconsin, November 2020 to December 2021.
McLean HQ, McClure DL, King JP, Meece JK, Pattinson D, Neumann G, Kawaoka Y, Rolfes MA, Belongia EA. Influenza Other Respir Viruses. 2022 Jul;16(4):607-612. doi: 10.1111/irv.12970. Epub 2022 Feb 18. PMID: 35178857

Effectiveness of a fourth dose of **covid-19** mRNA **vaccine** against the omicron variant among long term care residents in Ontario, Canada: test negative design study.
Grewal R, Kitchen SA, Nguyen L, Buchan SA, Wilson SE, Costa AP, Kwong JC. BMJ. 2022 Jul 6;378:e071502. doi: 10.1136/bmj-2022-071502. PMID: 35793826

Medical decisions in organ donors and heart transplant candidates with history of **COVID-19** infection: An international practice survey.
Sadeh B, Ugolini S, Pinzon OW, Potapov EV, Selzman CH, Bader F, Zuckermann AO, Gomez-Mesa JE, Shah KS, Alharethi R, Morejon-Barragan P, Hanff T, Goldraich LA, Farrero M, MacDonald PS, Drakos S, Mehra MR, Stehlik J. Clin Transplant. 2022 Jul;36(7):e14733. doi: 10.1111/ctr.14733. Epub 2022 Jun 8. PMID: 35652422

The short term safety of **COVID-19** vaccines in Australia: AusVaxSafety active surveillance, February - August 2021.
Deng L, Glover C, Dymock M, Pillsbury A, Marsh JA, Quinn HE, Leeb A, Cashman P, Snelling TL, Wood N, Macartney K. Med J Aust. 2022 Jul 4. doi: 10.5694/mja2.51619. Online ahead of print. PMID: 35781813

The value of the basophil activation test in the evaluation of patients reporting allergic reactions to the BNT162b2 mRNA **COVID-19 vaccine**.
Labella M, Céspedes JA, Doña I, Shamji MH, Agache I, Mayorga C, Torres MJ. Allergy. 2022 Jul;77(7):2067-2079. doi: 10.1111/all.15148. Epub 2021 Oct 31. PMID: 34689351

Coronavirus disease 2019 **vaccine** administration in patients with reported reactions to polyethylene glycol- and polysorbate-containing therapeutics.
Otani IM, Tsao LR, Tang M. Ann Allergy Asthma Immunol. 2022 Jul;129(1):88-94.e1. doi: 10.1016/j.anai.2022.03.006. Epub 2022 Mar 12. PMID: 35288274

Use of Recently Vaccinated Individuals to Detect Bias in Test-Negative Case-Control Studies of **COVID-19 Vaccine** Effectiveness.
Hitchings MDT, Lewnard JA, Dean NE, Ko AI, Ranzani OT, Andrews JR, Cummings DAT. Epidemiology. 2022 Jul 1;33(4):450-456. doi: 10.1097/EDE.0000000000001484. Epub 2022 Apr 1. PMID: 35384900

Hybrid immunity against **COVID-19** in different countries with a special emphasis on the Indian scenario during the Omicron period.
Bhattacharya M, Sharma AR, Dhama K, Agoramoorthy G, Chakraborty C. Int Immunopharmacol. 2022 Jul;108:108766. doi: 10.1016/j.intimp.2022.108766. Epub 2022 Apr 7. PMID: 35413676

A pre-**vaccine** analysis using the Health Belief Model to explain parents' willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs.
Reindl D, Catma S. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul;22(5):753-761. doi: 10.1080/14737167.2022.2045957. Epub 2022 Mar 4. PMID: 35192425

Chronic spontaneous urticaria following **COVID-19** vaccination.
de Montjoye L, Herman A, Baeck M. JAAD Case Rep. 2022 Jul;25:35-38. doi: 10.1016/j.jdcr.2022.05.011. Epub 2022 May 21. PMID: 35615160

Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of **COVID-19 vaccine**.
Tedeschi SK, Stratton J, Ellrodt JE, Whelan MG, Hayashi K, Yoshida K, Chen L, Adejoorin I, Marks KE, Jonsson AH, Rao DA, Solomon DH. Ann Rheum Dis. 2022 Jul;81(7):1045-1048. doi: 10.1136/annrheumdis-2022-222232. Epub 2022 Feb 15. PMID: 35168944

SARS-CoV-2 variants and the global pandemic challenged by **vaccine** uptake during the emergence of the Delta variant: A national survey seeking **vaccine** hesitancy causes.
AlJamaan F, Temsah MH, Alhasan K, Alenezi S, Alhaboob A, Alrabiaah A, Batais M, Alshahrani F, Assiri RA, Bafaqih H, Alaraj A, Al Qadrah B, Alhaidary A, Saad K, Saddik B, Halwani R, Rabaan AA, Al-Subaie S, Barry M, Al-Tawfiq JA. J Infect Public Health. 2022 Jul;15(7):773-780. doi: 10.1016/j.jiph.2022.06.007. Epub 2022 Jun 17. PMID: 35728424

Immunogenicity 6 months post **COVID-19** mRNA-vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF-inhibitors.
Dimopoulou D, Tsolia MN, Spyridis N, Maritsi DN. Rheumatology (Oxford). 2022 Jul 5:keac352. doi: 10.1093/rheumatology/keac352. Online ahead of print. PMID: 35788275

Development of a Practice-based Community Outreach Intervention to Prevent Inequities in **COVID-19** Vaccinations.
Gonzalez CJ, Meltzer K, Jabri A, Zhu JJ, Lau JD, Pelzman F, Tung J. Am J Med Qual. 2022 Jul-Aug 01;37(4):348-355. doi: 10.1097/JMQ.0000000000000049. Epub 2022 Mar 16. PMID: 35353474

Comparison of anti-SARS-CoV-2 IgG and IgA antibody responses post complete vaccination, 7 months later and after 3rd dose of the BNT162b2 **vaccine** in healthy adults.
Rastawicki W, Juszczyk G, Gierczyński R, Zasada AA. J Clin Virol. 2022 Jul;152:105193. doi: 10.1016/j.jcv.2022.105193. Epub 2022 May 27. PMID: 35660747

The long road of pandemic **vaccine** development to rollout: A systematic review on the lessons learnt from the 2009 H1N1 influenza pandemic.
Ankomah AA, Moa A, Chughtai AA. Am J Infect Control. 2022 Jul;50(7):735-742. doi: 10.1016/j.ajic.2022.01.026. Epub 2022 Feb 4. PMID: 35131349

Exacerbation of psoriasis following vaccination with the Pfizer-BioNTech BTN162b2 mRNA **COVID-19 vaccine** during risankizumab treatment.
Tsunoda K, Watabe D, Amano H. J Dermatol. 2022 Jul 7. doi: 10.1111/1346-8138.16505. Online ahead of print. PMID: 35795974

Third dose of **COVID-19 vaccine** in diabetes: Relevance of good metabolic control to improve its efficacy.
Pieralice S, D'Onofrio L, Pozzilli P, Buzzetti R. Diabetes Metab Res Rev. 2022 Jul;38(5):e3533. doi: 10.1002/dmrr.3533. Epub 2022 Apr 30. PMID: 35468252

Higher antibody responses after mRNA-based **vaccine** compared to inactivated **vaccine** against SARS-CoV-2 in Behcet's syndrome.
Ozdede A, Nohut OK, Atli Z, Tok YT, Guner S, Yilmaz E, Ucar D, Uygunoglu U, Hamuryudan V, Seyahi E. Rheumatol Int. 2022 Jul 2. doi: 10.1007/s00296-022-05164-7. Online ahead of print. PMID: 35779083

A Third Dose of mRNA **COVID-19 Vaccine** Significantly Enhances Anti-SARS-CoV-2 Spike IgG Response in Nursing Home Residents in Italy.
Fedele G, Palmieri A, Malara A, Damiano C, Di Lonardo A, Schiavoni I, Leone P, Panduri G, Minchella P, Talarico F, Palamara AT, Stefanelli P, Incalzi RA, Onder G; GeroCovid Vax Study Group. J Am Med Dir Assoc. 2022 Jul;23(7):1114-1115. doi: 10.1016/j.jamda.2022.05.006. Epub 2022 May 16. PMID: 35661654

Atrial fibrillation with aberrant ventricular conduction after receiving Bamlanivimab/Etesevimab: a case report.
Palazzo AG, Zizza A, Nuzzo M, Urciuoli C, Scardia S, Romano A, Guido M, Grima P. Curr Med Res Opin. 2022 Jul;38(7):1055-1057. doi: 10.1080/03007995.2022.2081450. Epub 2022 Jun 1. PMID: 35608093

**COVID-19 vaccine** breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan; a retrospective cohort study.
Almufty HB, Mamani MMA, Ali AH, Merza MA. J Med Virol. 2022 Jul 10. doi: 10.1002/jmv.27985. Online ahead of print. PMID: 35811398

Propolis efficacy on SARS-COV viruses: a review on antimicrobial activities and molecular simulations.
Ghosh S, Al-Sharify ZT, Maleka MF, Onyeaka H, Maleke M, Maolloum A, Godoy L, Meskini M, Rami MR, Ahmadi S, Al-Najjar SZ, Al-Sharify NT, Ahmed SM, Dehghani MH. Environ Sci Pollut Res Int. 2022 Jul 6:1-20. doi: 10.1007/s11356-022-21652-6. Online ahead of print. PMID: 35794320

D-dimers-"Normal" Levels versus Elevated Levels Due to a Range of Conditions, Including "D-dimeritis," Inflammation, Thromboembolism, Disseminated Intravascular Coagulation, and **COVID-19**.
Thachil J, Favaloro EJ, Lippi G. Semin Thromb Hemost. 2022 Jul 8. doi: 10.1055/s-0042-1748193. Online ahead of print. PMID: 35803265

Low antispike antibody levels correlate with poor outcomes in **COVID-19** breakthrough hospitalizations.
Sanghavi DK, Bhakta S, Wadei HM, Bosch W, Cowart JB, Carter RE, Shah SZ, Pollock BD, Neville MR, Oman SP, Speicher L, Siegel J, Scindia AD, Libertin CR, Kunze KL, Johnson PW, Matson MW, Franco PM. J Intern Med. 2022 Jul;292(1):127-135. doi: 10.1111/joim.13471. Epub 2022 Mar 24. PMID: 35194861

Chest Pain with New Abnormal Electrocardiogram Development after Injection of **COVID-19 Vaccine** Manufactured by Moderna.
Takase B, Hayashi K, Hisada T, Tsuchiya T, Masaki N, Nagata M. Intern Med. 2022 Jul 1;61(13):2089-2090. doi: 10.2169/internalmedicine.8711-21. Epub 2021 Dec 4. PMID: 34866106

SARS-CoV-2 the ASIA virus (Autoimmune/autoinflammatory Syndrome Induced by Adjuvants), the risk of infertility and **vaccine** hesitancy.

Ameratunga R. Expert Rev Vaccines. 2022 Jul 1:1-8. doi: 10.1080/14760584.2022.2089120. Online ahead of print. PMID: 35695410

Minimal change glomerulonephritis following the second dose of the Moderna **COVID-19 vaccine**.
Park HJ, An WS, Rha SH, Kim SE, Lee SM. QJM. 2022 Jul 9;115(7):490-491. doi: 10.1093/qjmed/hcac094. PMID: 35380707

Antinucleocapsid Antibodies After SARS-CoV-2 Infection in the Blinded Phase of the Randomized, Placebo-Controlled mRNA-1273 **COVID-19 Vaccine** Efficacy Clinical Trial.
Follmann D, Janes HE, Buhule OD, Zhou H, Girard B, Marks K, Kotloff K, Desjardins M, Corey L, Neuzil KM, Miller JM, El Sahly HM, Baden LR. Ann Intern Med. 2022 Jul 5:M22-1300. doi: 10.7326/M22-1300. Online ahead of print. PMID: 35785530

Correction: *Immunogenicity and safety of the BNT162b2 mRNA **COVID-19 vaccine** in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study*.
[No authors listed] Ann Rheum Dis. 2022 Jul;81(7):e133. doi: 10.1136/annrheumdis-2021-220647corr1. PMID: 35793261

The Protective Effect of Coronavirus Disease 2019 (**COVID-19**) Vaccination on Postacute Sequelae of **COVID-19**: A Multicenter Study From a Large National Health Research Network.
Zisis SN, Durieux JC, Mouchati C, Perez JA, McComsey GA. Open Forum Infect Dis. 2022 May 7;9(7):ofac228. doi: 10.1093/ofid/ofac228. eCollection 2022 Jul. PMID: 35818362

Indeterminate mycobacterium tuberculosis QuantiFERON post Moderna mRNA **Covid-19** vaccination.
Wang SSY. Indian J Tuberc. 2022 Jul;69(3):369-370. doi: 10.1016/j.ijtb.2022.03.019. Epub 2022 Mar 31. PMID: 35760490

Antibody responses and risk factors associated with impaired immunological outcomes following two doses of BNT162b2 **COVID-19** vaccination in patients with chronic pulmonary diseases.
Harboe ZB, Hamm SR, Pérez-Alós L, Sivapalan P, Priemé H, Wilcke T, Kjeldgaard P, Shaker S, Svorre Jordan A, Møller DL, Heftdal LD, Madsen JR, Bayarri-Olmos R, Hansen CB, Pries-Heje MM, Hasselbalch RB, Fogh K, Armenteros JJA, Hilsted L, Sørensen E, Lindegaard B, Browatzki A, Biering-Sørensen T, Frikke-Schmidt R, Ostrowski SR, Iversen KK, Bundgaard H, Nielsen SD, Garred P, Jensen JS. BMJ Open Respir Res. 2022 Jul;9(1):e001268. doi: 10.1136/bmjresp-2022-001268. PMID: 35793836

Risk of acute liver injury following the mRNA (BNT162b2) and inactivated (CoronaVac) **COVID-19** vaccines.
Wong CKH, Mak LY, Au ICH, Lai FTT, Li X, Wan EYF, Chui CSL, Chan EWY, Cheng WY, Cheng FWT, Yuen MF, Wong ICK. J Hepatol. 2022 Jul 8:S0168-8278(22)02931-2. doi: 10.1016/j.jhep.2022.06.032. Online ahead of print. PMID: 35817224

Changing characteristics over time of individuals receiving **COVID-19** vaccines in Denmark: A population-based descriptive study of **vaccine** uptake.
Reilev M, Olesen M, Kildegaard H, Støvring H, Andersen JH, Hallas J, Lund LC, Ladebo L, Ernst MT, Damkier P, Jensen PB, Pottegård A, Rasmussen L. Scand J Public Health. 2022 Jul 7:14034948221108246. doi: 10.1177/14034948221108246. Online ahead of print. PMID: 35799465

Unilateral Acute Idiopathic Blind Spot Enlargement following Second Dose of **Covid-19** mRNA **Vaccine**.
Shen C, Tennant M. Ocul Immunol Inflamm. 2022 Jul 8:1-3. doi: 10.1080/09273948.2022.2090964. Online ahead of print. PMID: 35801911

The Elderly Should Be Immunized With the **COVID-19 Vaccine** in China.
Zhou X, Xiang G, Chen L, Xiao Y, Cheng Z, Mou H. Asia Pac J Public Health. 2022 Jul 9:10105395221110964. doi: 10.1177/10105395221110964. Online ahead of print. PMID: 35815574

The Impact of Vaccination Against SARS-CoV-2 Virus on the Outcome of **COVID-19** Disease.
AlKhafaji DM, Al Argan RJ, AlBahrani S, Alwaheed AJ, Alqatari SG, Al Elq AH, Albaker W, Alwazzeh M, AlSulaiman AS, AlSulaiman RS, Almadan HM, Alhammad AA, Almajid AN, Hakami FH, Alanazi WK. Infect Drug Resist. 2022 Jul 2;15:3477-3489. doi: 10.2147/IDR.S365179. eCollection 2022. PMID: 35813086

Comparative assessment of myocarditis and pericarditis reporting rates related to mRNA **COVID-19** vaccines in Europe and the United States.
Hatziantoniou S, Anastassopoulou C, Lazaros G, Vasileiou K, Tsioufis C, Tsakris A. Expert Rev Vaccines. 2022 Jul 11. doi: 10.1080/14760584.2022.2100765. Online ahead of print. PMID: 35815358

Generalized pustular psoriasis flare in a patient affected by plaque psoriasis after BNT162b2 mRNA **COVID-19 vaccine**, successfully treated with risankizumab.
Pavia G, Gargiulo L, Spinelli F, Avagliano J, Valenti M, Borroni RG, Costanzo A, Narcisi A. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e502-e505. doi: 10.1111/jdv.18032. Epub 2022 Mar 3. PMID: 35224780

A Social Media–Based Public Health Campaign Encouraging **COVID-19** Vaccination Across the United States.
Hunt IV, Dunn T, Mahoney M, Chen M, Nava V, Linos E. Am J Public Health. 2022 Jul 7:e1-e4. doi: 10.2105/AJPH.2022.306934. Online ahead of print. PMID: 35797502

Cardiac magnetic resonance findings in acute myocarditis after mRNA **COVID-19** vaccination.
Sano M, Murai R, Kim K, Furukawa Y. J Cardiol Cases. 2022 Jul;26(1):17-20. doi: 10.1016/j.jccase.2022.01.015. Epub 2022 Feb 11. PMID: 35169401

Use of Random Domain Intercept Technology to Track **COVID-19** Vaccination Rates in Real Time Across the United States: Survey Study.
Sargent RH, Laurie S, Weakland LF, Lavery JV, Salmon DA, Orenstein WA, Breiman RF. J Med Internet Res. 2022 Jul 1;24(7):e37920. doi: 10.2196/37920. PMID: 35709335

Humoral antibody response to the first dose of the ChAdOx1 nCoV-**19 vaccine** in Asian patients undergoing hemodialysis.
Tung KT, Peng YS, Hsu SP, Wu HY, Chiu YL, Yang JY, Pai MF, Shu KH, Pan SY, Lu HM, Lin WY, Liao CH, Chu FY, Tsai WC. Hemodial Int. 2022 Jul;26(3):369-376. doi: 10.1111/hdi.13011. Epub 2022 Apr 11. PMID: 35411681

Factors Associated with Delayed or Missed Second-Dose mRNA **COVID-19** Vaccination among Persons >12 Years of Age, United States.

Meng L, Murthy NC, Murthy BP, Zell E, Saelee R, Irving M, Fast HE, Roman PC, Schiller A, Shaw L, Black CL, Gibbs-Scharf L, Harris L, Chorba T. Emerg Infect Dis. 2022 Jul 7;28(8). doi: 10.3201/eid2808.220557. Online ahead of print. PMID: 35798008

Safety and immunogenicity of intramuscular, single-dose V590 (rVSV-SARS-CoV-2 **Vaccine**) in healthy adults: Results from a phase 1 randomised, double-blind, placebo-controlled, dose-ranging trial.
Robbins JA, Tait D, Huang Q, Dubey S, Crumley T, Cote J, Luk J, Sachs JR, Rutkowski K, Park H, Schwab R, Howitt WJ, Rondon JC, Hernandez-Illas M, O'Reilly T, Smith W, Simon J, Hardalo C, Zhao X, Wnek R, Cope A, Lai E, Annunziato P, Guris D, Stoch SA. EBioMedicine. 2022 Jul 6;82:104138. doi: 10.1016/j.ebiom.2022.104138. Online ahead of print. PMID: 35809371

Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis.
Muecksch F, Wise H, Templeton K, Batchelor B, Squires M, McCance K, Jarvis L, Malloy K, Furrie E, Richardson C, MacGuire J, Godber I, Burns A, Mavin S, Zhang F, Schmidt F, Bieniasz PD, Jenks S, Hatziioannou T. Lancet Microbe. 2022 Jul;3(7):e493-e502. doi: 10.1016/S2666-5247(22)00090-8. Epub 2022 May 27. PMID: 35636436

Ascertainment of vaccination status by self-report versus source documentation: Impact on measuring **COVID-19 vaccine** effectiveness.
Stephenson M, Olson SM, Self WH, Ginde AA, Mohr NM, Gaglani M, Shapiro NI, Gibbs KW, Hager DN, Prekker ME, Gong MN, Steingrub JS, Peltan ID, Martin ET, Reddy R, Busse LW, Duggal A, Wilson JG, Qadir N, Mallow C, Kwon JH, Exline MC, Chappell JD, Lauring AS, Baughman A, Lindsell CJ, Hart KW, Lewis NM, Patel MM, Tenforde MW; IVY Network Investigators. Influenza Other Respir Viruses. 2022 Jul 11. doi: 10.1111/irv.13023. Online ahead of print. PMID: 35818721

Safety of an inactivated, whole-virion **COVID-19 vaccine** (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series.
Wan EYF, Wang Y, Chui CSL, Mok AHY, Xu W, Yan VKC, Lai FTT, Li X, Wong CKH, Chan EWY, Lau KK, Cowling BJ, Hung IFN, Wong ICK. Lancet Healthy Longev. 2022 Jul;3(7):e491-e500. doi: 10.1016/S2666-7568(22)00125-8. Epub 2022 Jul 4. PMID: 35813276

Longitudinal humoral response in MS patients treated with cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA **vaccine**.
Brill L, Rechtman A, Shifrin A, Rozenberg A, Afanasiev S, Zveik O, Haham N, Levin N, Vaknin-Dembinsky A. Mult Scler Relat Disord. 2022 Jul;63:103863. doi: 10.1016/j.msard.2022.103863. Epub 2022 May 10. PMID: 35667316

Bilateral facial palsy with paresthesias, variant of Guillain-Barré syndrome following **COVID-19 vaccine**: A case series of 9 patients.
Castiglione JI, Crespo JM, Lecchini L, Silveira FO, Luis MB, Cotti N, Simison CJ, Aguirre F, Piedrabuena MA, Alonso RN, Azcona CL, Sosa PS, Maldonado E, Barroso F. Neuromuscul Disord. 2022 Jul;32(7):572-574. doi: 10.1016/j.nmd.2022.05.003. Epub 2022 May 11. PMID: 35644722

Generalized morphea following the **COVID vaccine**: A series of two patients and a bibliographic review.
Antoñanzas J, Rodríguez-Garijo N, Estenaga Á, Morelló Vicente A, España A, Aguado L. Dermatol Ther. 2022 Jul 10:e15709. doi: 10.1111/dth.15709. Online ahead of print. PMID: 35811413

Long-term outcome of patients with **vaccine**-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis.
Kehr S, Berg P, Müller S, Fiedler SA, Meyer B, Ruppert-Seipp G, Witzenhausen C, Wolf ME, Henkes HH, Oberle D, Keller-Stanislawski B, Funk MB. NPJ Vaccines. 2022 Jul 5;7(1):76. doi: 10.1038/s41541-022-00491-z. PMID: 35790739

Another case of generalized bullous fixed drug eruption following an adenoviral vector-based **COVID-19 vaccine** (ChAdOx1 nCov-**19**).
Ben Salem C, Khelif A, Sahnoun D, Ghariani N, Sriha B, Denguezli M. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e516-e517. doi: 10.1111/jdv.18059. Epub 2022 Mar 15. PMID: 35274363

ROCCA cohort study: Nationwide results on safety of Gam-**COVID**-Vac **vaccine** (Sputnik V) in the Republic of San Marino using active surveillance.
Di Valerio Z, La Fauci G, Soldà G, Montalti M, Lenzi J, Forcellini M, Barvas E, Guttmann S, Poluzzi E, Raschi E, Riccardi R, Fantini MP, Salussolia A, Gori D. EClinicalMedicine. 2022 Jul;49:101468. doi: 10.1016/j.eclinm.2022.101468. Epub 2022 May 20. PMID: 35614901

Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers.
Yamamoto S, Tanaka A, Ohmagari N, Yamaguchi K, Ishitsuka K, Morisaki N, Kojima M, Nishikimi A, Tokuda H, Inoue M, Tanaka S, Umezawa J, Okubo R, Nishimura K, Konishi M, Miyo K, Mizoue T. Prev Med. 2022 Jul 1;161:107123. doi: 10.1016/j.ypmed.2022.107123. Online ahead of print. PMID: 35787841

Mucosal **vaccine** delivery: A focus on the breakthrough of specific barriers.
Huang M, Zhang M, Zhu H, Du X, Wang J. Acta Pharm Sin B. 2022 Jul 6. doi: 10.1016/j.apsb.2022.07.002. Online ahead of print. PMID: 35818435

What Experts Think About Prostate Cancer Management During the **COVID-19** Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021.
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khauli RB, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke Onyeanunam N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Pablo Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. Eur Urol. 2022 Jul;82(1):6-11. doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17. PMID: 35393158

Case of lichen planus pigmentosus-inversus after Oxford-AstraZeneca **COVID-19 vaccine**: cause or coincidence?
Sun L, Duarte S, Soares-de-Almeida L. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e514-e516. doi: 10.1111/jdv.18058. Epub 2022 Mar 16. PMID: 35278243

Immunogenicity and reactogenicity against the SARS-CoV-2 variants following heterologous primary series involving CoronaVac, ChAdox1 nCov-**19** and BNT162b2 plus BNT162b2 booster vaccination: An open-label randomized study in healthy Thai adults.
Niyomnaitham S, Quan Toh Z, Wongprompitak P, Jansarikit L, Srisutthisamphan K, Sapsutthipas S, Jantraphakorn Y, Mingngamsup N, Licciardi PV, Chokephaibulkit K. Hum Vaccin Immunother. 2022 Jul 11:2091865. doi: 10.1080/21645515.2022.2091865. Online ahead of print. PMID: 35816053

Tailoring immunisation programmes in a time of SARS-CoV-2: What can be learnt by comparing the findings of childhood and **COVID-19 vaccine** evaluation studies in an underserved population?
Kasstan B, Letley L, Mounier-Jack S, Klynman N, Gaskell KM, Eggo RM, Marks M, Chantler T. Public Health Pract (Oxf). 2022 Jul 2:100287. doi: 10.1016/j.puhip.2022.100287. Online ahead of print. PMID: 35811646

Evaluation of antibody titer kinetics and SARS-CoV-2 infections in a large cohort of healthcare professionals ten months after administration of the BNT162b2 **vaccine**.
Ferrari D, Ambrosi A, Di Resta C, Tomaiuolo R, Locatelli M, Banfi G. J Immunol Methods. 2022 Jul;506:113293. doi: 10.1016/j.jim.2022.113293. Epub 2022 Jun 2. PMID: 35660546

A Case Report of MPO-ANCA-Associated Vasculitis Following Heterologous mRNA1273 **COVID-19** Booster Vaccination.
Kim BC, Kim HS, Han KH, Han SY, Jo HA. J Korean Med Sci. 2022 Jul 4;37(26):e204. doi: 10.3346/jkms.2022.37.e204. PMID: 35790206

Intractable alopecia areata following the second dose of **COVID-19** vaccination: Report of two cases.
Chen CH, Chen YY, Lan CE. Dermatol Ther. 2022 Jul 4:e15689. doi: 10.1111/dth.15689. Online ahead of print. PMID: 35789521

Correspondence on "Paroxysmal Supra-ventricular Ventricular Tachycardia after **COVID-19 Vaccine** Injection".
Mungmunpuntipantip R, Wiwanitkit V. New Microbes New Infect. 2022 Jul 2:101006. doi: 10.1016/j.nmni.2022.101006. Online ahead of print. PMID: 35815169

TAFRO syndrome with a fatal clinical course following BNT162b2 mRNA (Pfizer-BioNTech) **COVID-19** vaccination: A case report.
Yamada M, Sada RM, Kashihara E, Okubo G, Matsushita S, Manabe A, Tagawa S, Akebo H, Miyake H, Hatta K. J Infect Chemother. 2022 Jul;28(7):1008-1011. doi: 10.1016/j.jiac.2022.04.005. Epub 2022 Apr 11. PMID: 35428576

**Vaccine**-induced immune thrombotic thrombocytopenia in a male after Ad26.COV2.S vaccination presenting as cerebral venous sinus thrombosis.
Wu JF, Bajwa U, Hammad M. Platelets. 2022 Jul 4;33(5):797-800. doi: 10.1080/09537104.2022.2071854. Epub 2022 May 9. PMID: 35535430

Pityriasis rubra pilaris (type I) following ChAdOx1 **COVID-19 vaccine**: A report of two cases with successful treatment with oral isotretinoin.
Criado PR, Ianhez M, Rocha PS, Miot HA. J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e508-e510. doi: 10.1111/jdv.18055. Epub 2022 Mar 15. PMID: 35278239

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease and Transverse Myelitis Probably Associated With SARS-CoV-2 mRNA Vaccines: Two Case Reports.
Morena J, Gyang TV. Neurohospitalist. 2022 Jul;12(3):536-540. doi: 10.1177/19418744221090426. Epub 2022 Apr 17. PMID: 35755241

Immune Thrombocytopenic Purpura (ITP) Following Natural **COVID-19** Infection.
Santhosh S, Malik B, Kalantary A, Kunadi A. Cureus. 2022 Jul 5;14(7):e26582. doi: 10.7759/cureus.26582. eCollection 2022 Jul. PMID: 35815306

Cataracts in setting of multisystem inflammation after **COVID-19** vaccination.
Kim DH, Hsu D, Li Y, Sulewski ME. Am J Ophthalmol Case Rep. 2022 Jul 7:101654. doi: 10.1016/j.ajoc.2022.101654. Online ahead of print. PMID: 35818371

RBD decorated PLA nanoparticle admixture with aluminum hydroxide elicit robust and long lasting immune response against SARS-CoV-2.
Meena J, Singhvi P, Srichandan S, Dandotiya J, Verma J, Singh M, Ahuja R, Panwar N, Wani TQ, Khatri R, Siddiqui G, Gupta A, Samal S, Panda AK. Eur J Pharm Biopharm. 2022 Jul;176:43-53. doi: 10.1016/j.ejpb.2022.05.008. Epub 2022 May 17. PMID: 35589003

Unilateral recurrent central serous chorioretinopathy (CSCR) following **COVID-19** vaccination- A multimodal imaging study.
Sanjay S, Acharya I, Kawali A, Shetty R, Mahendradas P. Am J Ophthalmol Case Rep. 2022 Sep;27:101644. doi: 10.1016/j.ajoc.2022.101644. Epub 2022 Jul 6. PMID: 35818570

# Patentes registradas en Patentscope

Estrategia de búqueda: *Vaccine in the title or abstract AND 20220701:20220711 as the publication date 45 records.*

1.WO/2022/143901METHOD FOR PREPARING NOVEL CORONAVIRUS VACCINE AND METHOD FOR EVALUATING EFFECTIVENESS THEREOF
WO - 07.07.2022
Clasificación Internacional A61K 39/215 Nº de solicitud PCT/CN2021/143090 Solicitante INSTITUTE OF MEDICAL BIOLOGY CHINESE ACADEMY OF MEDICAL SCIENCES & PEKING UNION MEDICAL COLLEGE Inventor/a LI, Qihan
Provided in the present invention are a method for preparing a novel coronavirus vaccine and a method for evaluating the effectiveness thereof. The novel coronavirus vaccine is an inactivated vaccine in which a part of a virus membrane is split so as to expose a nucleocapsid N antigen. The vaccine strain is inactivated twice during preparation, the first inactivation is carried out by means of using formaldehyde (HCHO), and then the second inactivation is carried out by means of using β-propiolactone (BPL). The method for evaluating the novel coronavirus vaccine comprises a plurality of detection methods comprising antibody neutralization, Elisa antibody determination and specific CTL detection.

2.4023235PHARMAZEUTISCHE ZUSAMMENSETZUNG ZUR BEHANDLUNG VON KREBS MIT VACCINIA-VIRUS UND GRANULOPOIESE-INHIBITOR ALS WIRKSTOFFE
EP - 06.07.2022
Clasificación Internacional A61K 35/768 Nº de solicitud 20859414 Solicitante BIONOXX INC Inventor/a HWANG TAE-HO

The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients. The pharmaceutical composition for treating cancer, comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients, of the present invention has a excellent anticancer effect and safety compared to the case of administering only the vaccinia virus. Therefore, the pharmaceutical composition comprising a vaccinia virus and a granulopoiesis inhibitor as active ingredients of the present invention may be efficiently utilized in treating cancer.

3.WO/2022/141266COMBINED VACCINE FOR PREVENTING HAND, FOOT AND MOUTH DISEASE, PREPARATION METHOD THEREFOR AND USE THEREOF
WO - 07.07.2022
Clasificación Internacional A61K 39/125 Nº de solicitud PCT/CN2020/141693 Solicitante SINOVAC BIOTECH CO., LTD. Inventor/a LI, Yajing
Provided is a combined vaccine for preventing hand, foot and mouth disease, comprising an inactivated enterovirus 71-type virus, and an inactivated coxsackievirus A group 16-type virus, 10-type virus, and 6-type virus. Also provided is a method for preparing the combined vaccine, and the prepared vaccine has a good adsorption effect and stability. The above-mentioned multiple antigens do not interfere with each other in terms of antigenicity and immune effect after immunizing the object, and also have a good immunogenicity and safety. The use of the combined vaccine can significantly simplify the vaccination procedure, improve the inoculation efficiency, and reduce the cost.

4.20220211837LIVE ATTENUATED INFLUENZA VACCINE COMPOSITION AND PROCESS FOR PREPARATION THEREOF
US - 07.07.2022
Clasificación Internacional A61K 39/145 Nº de solicitud 17429965 Solicitante SERUM INSTITUTE OF INDIA PVT LTD. Inventor/a Rajeev Mhalasakant DHERE The present disclosure provides compositions and methods for manufacturing and obtaining a live attenuated Influenza vaccine (LAIV) composition that can be delivered intranasally to provide protection against influenza virus infection. Said LAIV strains are based on cold adapted, temperature sensitive and attenuated phenotypes of master donor viruses (MDVs) containing the surface glycoprotein genes of the wild type pandemic or seasonal influenza strains. Also, said LAIV strains are further adapted to grow in MDCK cells (Madin Darby canine kidney cells). The use of eggs is avoided in large scale vaccine manufacturing. The purification process is devoid of chromatography steps. The said LAIV composition includes one or more live attenuated influenza vaccine virus and is devoid of polymers and surfactants.

5.WO/2022/143993NEISSERIA MENINGITIDIS VACCINE AND USE THEREOF
WO - 07.07.2022
Clasificación Internacional A61K 39/095 Nº de solicitud PCT/CN2021/143737 Solicitante FOUNDATION THERAPY LIMITED Inventor/a ZHENG, Bao
The present invention relates to a vaccine for preventing or treating a Neisseria meningitidis infection or diseases induced thereby, the use thereof and a method therefor. The present invention relates to a Neisseria meningitidis vaccine, which comprises a bacterial ghost and a factor H binding protein (fHBP), and is used for preventing or treating a Neisseria meningitidis infection or diseases induced thereby, such as invasive meningococcal disease (IMD). In addition, the present invention relates to the use of a composition, comprising a bacterial ghost and an fHBP, in the preparation of a vaccine for preventing or treating a Neisseria meningitidis infection or diseases induced thereby, such as IMD. Furthermore, the present invention relates to a method for preventing or treating a Neisseria meningitidis infection or diseases induced thereby, such as IMD, which method comprises administering a prophylactically effective dose or therapeutically effective dose of the Neisseria meningitidis vaccine to a subject.

6.20220211844WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME
US - 07.07.2022
Clasificación Internacional A61K 39/39 Nº de solicitud 17600919 Solicitante Sumitomo Dainippon Pharma Co., Ltd. Inventor/a Hitoshi Ban
The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.

7.WO/2022/146125DNA VACCINE COMPOSITION COMPRISING HEPATITIS VIRUS B-DERIVED MUTANT MOLECULE AND PATHOGEN- OR TUMOR-ASSOCIATED ANTIGEN MOLECULE AND USE THEREOF
WO - 07.07.2022
Clasificación Internacional C07K 14/005 Nº de solicitud PCT/KR2022/000053 Solicitante SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION Inventor/a KIM, Byoung Jun
The present invention relates to a DNA vaccine composition comprising a hepatitis virus B-derived mutant molecule and an antigen molecule of a pathogen or a tumor-associated antigen protein, and a use thereof as a prophylactic or therapeutic composition for pathogen infection or tumor. Including the hepatitis virus B-derived mutant molecule therein, a vaccine composition according to an aspect exhibits a remarkable effect of activating humoral immunity and cellular immunity, compared to conventional DNA vaccines and as such, can be advantageously used as a prophylactic or therapeutic vaccine for pathogenic infections, for example, viral infections or bacterial infections or tumors.

8.20220211839FELINE LEUKEMIA VIRUS VACCINE
US - 07.07.2022
Clasificación Internacional A61K 39/21 Nº de solicitud 17698205 Solicitante Intervet Inc. Inventor/a Ian Tarpey
The present invention provides a vaccine for feline leukemia virus and methods of making and using the vaccine alone, or in combinations with other protective agents.

9.202217013406METHODS FOR PREVENTING DENGUE AND HEPATITIS A
IN - 01.07.2022
Clasificación Internacional A61K / Nº de solicitud 202217013406 Solicitante TAKEDA VACCINES, INC. Inventor/a WALLACE, Derek
The invention relates to a method for preventing dengue disease and hepatitis A in a subject or subject population by simultaneously administering a unit dose of a dengue vaccine composition and a hepatitis A vaccine on the same day. The unit dose of a dengue vaccine composition includes constructs of each dengue serotype, such as TDV-1, TDV-2, TDV-3 and TDV-4, at various concentrations in order to improve protection from dengue infection.

10.4021491ANTIMIKROBIELLE IMPFSTOFFZUSAMMENSETZUNG
EP - 06.07.2022
Clasificación Internacional A61K 39/08 Nº de solicitud 20857274 Solicitante ALOPEXX INC Inventor/a DABORA REBECCA
This invention is directed to antimicrobial vaccine compounds and compositions comprising oligosaccharide β-(1→6)- glucosamine groups having from 3 to 12 glucosamine units linked through a linker group to tetanus toxoid wherein the toxoid is primarily in its monomeric form This invention is also directed to vaccine compositions that provide natural immunity against microbes possessing a cell wall structure tha comprises oligosaccharide N-acetyl-β-(1→6)-glucosamine (PNAG) structures.

11.WO/2022/146174METHOD OF OBTAINING BETULIN AS AN ADJUVANT IN A VACCINE AGAINST CORONAVIRUS SARS-COV-2

  

WO - 07.07.2022
Clasificación Internacional A61K 47/10 Nº de solicitud PCT/RU2021/000341 Solicitante BETUVAKS LIMITED LIABILITY COMPANY Inventor/a ISAEV, Artur Alexandrovich
The invention relates to biotechnology, and specifically to a method for creating the adjuvant betulin, suitable for preparing a vaccine against coronavirus SARS-CoV-2. The method consists in sterilizing filtration of a solution of betulin in tetrahydrofuran through a nylon membrane with a pore diameter of 0.22 μm, decreasing the tetrahydrofuran content by adding a 25-fold volume of sterile 0.01 M tris-buffer (pH 9.0+0.1), and subsequently homogenizing by ultrasound until a homogeneous suspension results, forming spherical amorphous homogeneous particles suitable for binding proteins of the SARS-CoV-2 virus. The proposed technique makes it possible to produce betulin with high sterility and immunogenicity, which improves the quality of the vaccine against the coronavirus.

12.WO/2022/147044TEMPERATURE STABLE NUCLEIC ACID METHOD FOR PREPARING VACCINE
WO - 07.07.2022
Clasificación Internacional A61K 39/39 Nº de solicitud PCT/US2021/065395 Solicitante GJERDE, Doulas, T. Inventor/a GJERDE, Doulas, T.
Nucleic acid and the nanocomplex reagents are combined to create a vaccine. They are stable and stored separately without degradation. The vaccine components can be stored at a wide range of temperatures. The nucleic acids are stabilized and stored in a column, syringe, vial or chamber as a solid, lyophilized or precipitated. They may be stored on a solid phase surface through electrostatic forces, non-polar interactions, hydrogen bonding, polar interactions or any other mechanism. The solid surface may be media in a column which may be contained in a syringe. Nucleic acid vaccines are prepared by a two-step process. The nucleic acid component is first stabilized and then mixed with nanocomplex reagents, particle forming reagents or other reagents.

13.4023234PHARMAZEUTISCHE ZUSAMMENSETZUNG MIT VACCINIA-VIRUS UND HYDROXYHARNSTOFF ALS WIRKSTOFF ZUR BEHANDLUNG VON KREBS
EP - 06.07.2022
Clasificación Internacional A61K 35/768 Nº de solicitud 19942788 Solicitante BIONOXX INC Inventor/a HWANG TAE-HO
The present invention relates to a pharmaceutical composition comprising Vaccinia virus and hydroxyurea as active ingredients for prevention or treatment of cancer. The pharmaceutical composition comprising Vaccinia virus and hydroxyurea as active ingredients for treatment of cancer according to the present invention exhibits higher anticancer effects and safety than the conventional administration of Vaccinia virus alone. Therefore, the pharmaceutical composition comprising Vaccinia virus and hydroxyurea as active ingredients according to the present invention may be advantageously used for treating cancer.

14.4023244INFLUENZA-IMPFSTOFFZUSAMMENSETZUNG AUF DER GRUNDLAGE EINER NEUARTIGEN NUKLEINSÄURE
EP - 06.07.2022
Clasificación Internacional A61K 39/145 Nº de solicitud 20857861 Solicitante NA VACCINE INST Inventor/a KIM MEE HYEIN
Provided is an influenza vaccine composition based on a novel ribonucleic acid having a dual function of serving as an immunity-boosting agent and capturing antigens.

15.WO/2022/144353IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SWINE DYSENTERY
WO - 07.07.2022
Clasificación Internacional A61K 39/02 Nº de solicitud PCT/EP2021/087718 Solicitante HIPRA SCIENTIFIC, S.L.U. Inventor/a OSORIO ARGUELLO, Jesús María

The invention relates to an immunogenic or vaccine composition comprising an inactivated bacterium from the species Brachyspira hyodysenteriae, to a method for producing said composition and to the medical use of this composition for inducing an immune response against a bacterium from the species Brachyspira hyodysenteriae or for protecting against an infection caused by a bacterium from the species Brachyspira hyodysenteriae. Further, the invention relates to a method for selecting a bacterium from the species Brachyspira hyodysenteriae useful for manufacturing a vaccine against swine dysentery.

16.4021925VERFAHREN ZUR ERHÖHUNG DER WIRKSAMKEIT VON IMPFSTOFFEN
EP - 06.07.2022
Clasificación Internacional C07K 14/195 Nº de solicitud 20859200 Solicitante GENOME PROT INC Inventor/a GUDKOV ANDREI
The present invention relates, in part, to compositions and methods for enhancement of an immune response and for increased vaccine efficacy by stimulation of the TLR5 receptor, for example, with a recombinant TLR5 agonist (*e.g.*, a flagellin-based agent or variant thereof).

17.20220211835Replication Deficient Adenoviral Vectors for HIV Vaccine Applications
US - 07.07.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 17604329 Solicitante THE WISTAR INSTITUTE Inventor/a Hildegund C.J. Ertl
The invention includes compositions and methods of generating a chimpanzee-derived adenovirus serotype AdC6 or AdC7 vector vaccine, wherein an early gene E1 genomic region is deleted, and wherein the nucleic acid sequence further comprises an expression cassette comprising a promoter sequence operably linked to a sequence encoding a heterologous protein, wherein the heterologous protein is at least one HIV protein selected from the group consisting of gp140 and Gag, wherein gp140 is from a Chinese HIV clade selected from the group consisting of B, AE, BC and C, and wherein Gag is from a Chinese HIV clade B. Furthermore, the invention encompasses a pharmaceutical composition for vaccinating a mammal as well as a protein expression system.

18.4021923HEPATITIS-B-VIRUS-IMPFSTOFFE
EP - 06.07.2022
Clasificación Internacional C07K 14/02 Nº de solicitud 20830016 Solicitante VIR BIOTECHNOLOGY INC Inventor/a BRUENING ERIC
The present disclosure relates to isolated polynucleotides and polypeptides, and related hepatitis B virus (HBV) vaccines. The present disclosure also relates to viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines described herein. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area are also provided herein.

19.2602562CRA4S1 gene, encoded CRA4S1 protein, and application
GB - 06.07.2022
Clasificación Internacional C07K 14/195 Nº de solicitud 202200745 Solicitante XIAOJU SHI Inventor/a XIAOJU SHI
Provided are a cra4S1 gene, an encoded cra4S1 protein, and a vaccine or drug containing the cra4S1 protein or a fragment thereof. A nucleotide sequence of the cra4S1 gene is represented by SEQ ID NO. 1. The vaccine combines the specific target of an outer membrane protein of Porphyromonas gingivalis and the antigen component of the bacterial conserved region, which has an immune prevention and protection effect on the body.

  

20.4021471GENETISCH VERÄNDERTE ONCOLYTISCHE VACCINIAVIREN UND VERWENDUNGSVERFAHREN DAFÜR
EP - 06.07.2022
Clasificación Internacional A61K 35/768 Nº de solicitud 20799848 Solicitante ASTELLAS PHARMA INC Inventor/a NAKAO SHINSUKE
The present invention provides pharmaceutical compositions comprising an oncolytic vaccinia virus and methods of using such pharmaceutical compositions for treating a subject having a cancer.

21.WO/2022/146484STABLE CORONAVIRUS PROTEINS AND VACCINE COMPOSITIONS THEREOF
WO - 07.07.2022
Clasificación Internacional C07K 14/165 Nº de solicitud PCT/US2021/037341 Solicitante UNIVERSITY OF WASHINGTON Inventor/a ELLIS, Daniel
Provided herein are compositions and methods comprising mutated coronavirus "S" spike proteins or receptor binding domains thereof that have an increased expression level, yield and stability compared to its corresponding native or wild-type coronavirus spike protein under the same expression, culture or storage conditions. These mutated spike proteins can be used for generating a protein-based vaccine against one or more coronaviruses.

22.2022204267Vaccine compositions
AU - 07.07.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 2022204267 Solicitante Bharat Biotech International Limited Inventor/a ELLA, Krishna Murthy
The present disclosure provides vaccine compositions for prophylaxis and treatment of Zika virus infections comprising Zika virus antigens in immunogenic compositions, and in combination of Zika antigens with one or more arbovirus antigens such as Chikungunya virus and Japanese encephalitis virus antigens, methods of preparation and production of such compositions for use as vaccines for eliciting immune response in mammals against the above mentioned pathogens.

23.20220215952WIRELESS PATIENT HEALTH MONITORING AND MANAGEMENT SYSTEM USING IOT AND 6G TECHNOLOGY
US - 07.07.2022
Clasificación Internacional G16H 40/67 Nº de solicitud 17684705 Solicitante Sami Bourouis Inventor/a Sami Bourouis
The system comprises a plurality of sensing nodes for detecting real time health parameters of patients; a user interface having a plurality of entry fields allotted to a plurality of medical practitioners and pharmacy shops for updating an information of treatment, medication, disease, stage of disease, treatment duration, and the like; a 6G transceiver for wirelessly communicating with the plurality of sensing nodes and user interfaces; a blockchain-based memory for storing the real time health parameters and the information of treatment, medication, disease, stage of disease, treatment duration, and the like; and a central processing unit for generating a health record of each patients thereby storing into the blockchain-based memory such that a medical practitioner is allowed to access the stored data to study the health record of a patient before treatment or before suggesting any medication/vaccine to avoid the complications or any side effect.

24.2768524PD-L1-baseret immunterapi
DK - 04.07.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 12780408 Solicitante IO BIOTECH ApS Inventor/a Andersen, Mads Hald
The present invention relates to the field of prophylaxis and therapy of clinical conditions including cancer, autoimmune diseases and infectious diseases. In particular there is provided vaccine compositions

comprising PD-L1 or peptide fragments thereof that are capable of eliciting immune responses useful in treatment of cancer, autoimmune diseases or infectious diseases.

25.4021409WIRKSAMKEIT EINES THERAPEUTISCHEN MITTELS UND DESSEN VERABREICHUNGSWEG
EP - 06.07.2022
Clasificación Internacional A61K 9/00 Nº de solicitud 20853476 Solicitante ALTIMMUNE INC Inventor/a KRISHNAN VYJAYANTHI
Disclosed herein are methods for generating a protective immunogenic response via intranasal administration of an immunogenic composition (e.g., vaccine)/therapeutic immunogenic composition in a mammalian subject. Certain dosing positions of the subject during the administration of immunogenic agents, such that nostrils are tilted upwards, while in a modified sitting, reclining and/or supine posture, is surprisingly correlated with the generation of a strong immunogenic response in both humans and animals.

26.WO/2022/147142KLEBSIELLA PNEUMONIAE O-ANTIGEN GLYCOSYLATED PROTEINS AND METHODS OF MAKING AND USES THEREOF
WO - 07.07.2022
Clasificación Internacional A61K 47/65 Nº de solicitud PCT/US2021/065533 Solicitante VAXNEWMO LLC Inventor/a HARDING, Christian
Provided herein is a bioconjugate comprising a K. pneumoniae O-antigen covalently linked to a fusion protein comprising a ComP protein or a glycosylation tag fragment. The K. pneumoniae O-antigen bioconjugate of this disclosure can be used as a conjugate vaccine including multivalent conjugate vaccines comprising multiple K. pneumoniae O-antigens.

27.4021458NEUE VERWENDUNG VON CYCLISCHEN DINUKLEOTIDEN
EP - 06.07.2022
Clasificación Internacional A61K 31/7084 Nº de solicitud 20764629 Solicitante HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH Inventor/a GUZMAN CARLOS A
In a first aspect, the present invention relates to cyclic dinucleotide compounds, in particular, c-di AMP for use in a method of inducing or promoting an immune response in an individual wherein said individual is a neonate or infant. The compound according to the present invention is particularly useful for use in therapeutic or prophylactic vaccination. In a further aspect, pharmaceutical compositions comprising the compound according to the present invention as an adjuvant, a pharmaceutically active ingredient for use as defined herein, in particular, as an adjuvant in a vaccine for unborn children, neonates and infants are provided. Finally, the present invention relates to a kit comprising a compound according to the present invention as an adjuvant, an antigen comprising antigenic structure as active vaccination component, in particular, to the use of said kit in a use of preventing or treating a disease.

28.20220211828TARGET PEPTIDES FOR OVARIAN CANCER THERAPY AND DIAGNOSTICS
US - 07.07.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 17182886 Solicitante University of Virginia Patent Foundation Inventor/a Donald F. Hunt
A set of target peptides are presented by HLA A*0201 on the surface of ovarian cancer cells. They are envisioned to among other things (a) stimulate an immune response to the proliferative disease, e.g., ovarian cancer, (b) function as immunotherapeutics in adoptive T-cell therapy or as a vaccine, (c) facilitate antibody recognition of tumor boundaries in surgical pathology samples, (d) act as biomarkers for early detection and/or diagnosis of the disease, and (e) act as targets in the generation antibody-like molecules which recognize the target-peptide/MHC complex.

29.20220211836INACTIVATED VIRUS COMPOSITIONS AND ZIKA VACCINE FORMULATIONS

US - 07.07.2022
Clasificación Internacional A61K 39/12 Nº de solicitud 17609217 Solicitante Takeda Vaccines, Inc. Inventor/a Michael JOHNSON
The present invention relates to a liquid inactivated virus composition comprising: an inactivated whole Zika virus, at least one pharmaceutically acceptable buffer with a concentration of at least about 6.5 mM, and optionally a polyol, wherein said at least one pharmaceutically acceptable buffer does not comprise phosphate ions and vaccines derived therefrom.

30.WO/2022/143985PYRIDINE-2-AMINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION AND USE THEREOF
WO - 07.07.2022
Clasificación Internacional C07D 471/04 Nº de solicitud PCT/CN2021/143703 Solicitante TSINGHUA UNIVERSITY Inventor/a LIAO, Xuebin
Disclosed in the present invention are a pyridine-2-amine derivative and a pharmaceutical composition and use thereof. The pyridine-2-amine derivative can be used as a TLR8 selective agonist, has the characteristics of high selectivity, strong activity and high safety, can be used for preventing and/or treating diseases related to TLR activity, for example, diseases caused by or related to pathogen infection, immunological diseases, inflammation, and tumors, can also be used for preparing a vaccine adjuvant to enhance immune response, and has better application prospects and research and development value.

31.WO/2022/143282NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION, OR KIT, AND USE THEREOF
WO - 07.07.2022
Clasificación Internacional C07K 14/08 Nº de solicitud PCT/CN2021/139930 Solicitante GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD. Inventor/a LI, Jianqiang
The present invention provides a GII.4-type Norovirus virus-like particle or an active fragment thereof, and a use thereof, the virus-like particle comprising or being composed of an amino acid sequence shown as SEQ ID NO: 4. The present invention further provides a composition or kit containing the GII.4-type Norovirus virus-like particle, and a use thereof. The objective of covering multiple valence types is achieved by using a single antigen of the present invention, the process difficulty of preparation of a pharmaceutical composition or vaccine can be reduced, and production costs are reduced. The present invention further provides a Norovirus immune composition or kit containing GII.2, GII.4, GII.6, and GII.17-type Norovirus virus-like particles or active fragments thereof, and a use thereof. According to the composition or kit containing four types of antigens, the antigens can generate a cross-immune effect on other valence types; and multiple popular valence types of Norovirus can be covered, and the cooperativity of an immune effect exists for the same cross-valence type among the four types of antigens.

32.4021938CR2 BINDENDE PROTEINE UND IHRE VERWENDUNG IN DER MEDIZINISCHEN THERAPIE
EP - 06.07.2022
Clasificación Internacional C07K 16/28 Nº de solicitud 20767985 Solicitante GLAXOSMITHKLINE IP DEV LTD Inventor/a BAILEY JAMES MATTHEW
The present invention provides CR2 binding proteins which bind to human CR2, pharmaceutical compositions comprising said CR2 binding proteins and their use in the treatment or prevention of autoimmune and/or inflammatory conditions, infectious diseases and malignancies associated with the Epstein-Barr virus (EBV); and their use as vaccine adjuvants/antigen carriers.

33.4023755KÜNSTLICHE NUKLEINSÄUREMOLEKÜLE ZUR VERBESSERTEN PROTEINEXPRESSION
EP - 06.07.2022
Clasificación Internacional C12N 15/67 Nº de solicitud 21209125 Solicitante CUREVAC AG Inventor/a THESS ANDREAS
The invention relates to an artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal. The invention further relates to a vector comprising the artificial nucleic acid molecule comprising an open reading frame and a 3'-UTR comprising at least one poly(A) sequence or a polyadenylation signal, to a cell comprising the artificial nucleic acid molecule or the vector, to a pharmaceutical composition comprising the artificial nucleic acid molecule or the vector and to a kit comprising the artificial nucleic acid molecule, the vector and/or the pharmaceutical composition. The invention also relates to a method for increasing protein production from an artificial nucleic acid molecule and to the use of a 3'-UTR for a method for increasing protein production from an artificial nucleic acid molecule. Moreover, the invention concerns the use of the artificial nucleic acid molecule, the vector, the kit or the pharmaceutical composition as a medicament, as a vaccine or in gene therapy.

34.4021493T-ZELL-EPITOPE VON HCMV UND VERWENDUNGEN DAVON
EP - 06.07.2022
Clasificación Internacional A61K 39/245 Nº de solicitud 20764373 Solicitante UNIV TUEBINGEN MEDIZINISCHE FAKULTAET Inventor/a NELDE ANNIKA
The present invention relates to relates to T cell epitope peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of viral infection. The present invention specifically relates to virus- associated T-cell peptide epitopes, alone or in combination with other virus-associated peptides that can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-viral immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

35.4021577IMPFSTOFFVIRUS GEGEN PORZINES REPRODUKTIVES UND RESPIRATORISCHES SYNDROM
EP - 06.07.2022
Clasificación Internacional A61P 31/14 Nº de solicitud 19789868 Solicitante ELANCO US INC Inventor/a WU STEPHEN QITU
The present invention relates to modified, live Porcine Reproductive and Respiratory Syndrome viruses. Viruses were genetically analyzed and selected based on phylogenetic grouping for modification by repeated passage in tissue culture. The modified, live viruses were assessed for the ability to provide protective immunity to heterologous viruses. The modified, live viruses are useful in vaccines, particularly in vaccines which can treat infection of swine by multiple heterologous viruses.

36.20220213150METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES
US - 07.07.2022
Clasificación Internacional C07K 14/005 Nº de solicitud 17702985 Solicitante TAKEDA VACCINES, INC. Inventor/a Joel R. HAYNES
The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The

disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample.

37.20220213149ANTIGEN DELIVERY PLATFORMS
US - 07.07.2022
Clasificación Internacional C07K 14/005 Nº de solicitud 17696143 Solicitante GLAXOSMITHKLINE BIOLOGICALS SA Inventor/a Michael FRANTI
This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development.

38.20220211838NUCLEIC ACID BASED COMBINATION VACCINES
US - 07.07.2022
Clasificación Internacional A61K 39/145 Nº de solicitud 17665704 Solicitante CureVac AG Inventor/a Cornelia OOSTVOGELS
The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

39.20220211841NUCLEIC ACID BASED COMBINATION VACCINES
US - 07.07.2022
Clasificación Internacional A61K 39/295 Nº de solicitud 17665772 Solicitante CureVac AG Inventor/a Cornelia OOSTVOGELS
The present invention is inter alia directed to pharmaceutical compositions comprising at least one nucleic acid encoding at least one antigenic peptide or protein from a Coronavirus, preferably a pandemic Coronavirus, and at least one nucleic acid encoding at least one antigenic peptide or protein from a further virus, e.g. an Influenza virus or an RSV virus. Pharmaceutical compositions provided herein are suitable for use in treatment or prophylaxis of an infection with at least one Coronavirus and at least one further virus infection, and may therefore be comprised in a combination vaccine. The nucleic acid sequences of the pharmaceutical compositions and combination vaccines are preferably in association with a polymeric carrier, a polycationic protein or peptide, or a lipid nanoparticle (LNP). The invention is also directed to first and second and further medical uses of the pharmaceutical compositions and combination vaccines, and to methods of treating or preventing a Coronavirus infection and a further virus infection.

40.789530FORMULATION OF A PEPTIDE VACCINE
NZ - 01.07.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 789530 Solicitante ISA PHARMACEUTICALS B.V. Inventor/a MULDER, Gwenn Eveline
The invention relates to a novel reconstitution composition, a pharmaceutical composition and kit of parts comprising said reconstitution composition. The invention further relates to a method of treatment using

said pharmaceutical composition and/or the pharmaceutical composition for use as a medicament. Also provided is a method for reconstituting dried peptides and a method for preparing a pharmaceutical composition using the reconstitution composition of the invention.

41.20220213448VIRAL VACCINES AND METHODS OF FORMING THE SAME
US - 07.07.2022
Clasificación Internacional C12N 7/00 Nº de solicitud 17706381 Solicitante NDSU Research Foundation Inventor/a Sheela RAMAMOORTHY
Provided herein is a method for producing an inactivated virus including a) heating the virus to a temperature sufficient to disrupt the virus membrane; b) exposing the virus of step (a) to a nucleic acid degrading enzyme; and c) cooling the virus to a temperature sufficient to reestablish the integrity of the virus membrane. Also provided herein is a vaccine produced using the instant method.

42.4022046REKOMBINANTE INFLUENZAVIREN MIT STABILISIERTEM HA ZUR REPLIKATION IN EIERN
EP - 06.07.2022
Clasificación Internacional C12N 7/00 Nº de solicitud 20768781 Solicitante WISCONSIN ALUMNI RES FOUNDATION WARF Inventor/a KAWAOKA YOSHIHIRO
Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.

43.789493NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS
NZ - 01.07.2022
Clasificación Internacional A61K 39/00 Nº de solicitud 789493 Solicitante IMMATICS BIOTECHNOLOGIES GMBH Inventor/a WAGNER, Philipp
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes comprising SEQ ID No 35, SEQ ID Nos. 1 to 34, SEQ ID Nos. 37 to 128, SEQ ID Nos. 130 to 417, and SEQ ID No. 419 to 772,alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

44.WO/2022/147173NANOEMULSION VACCINE COMPOSITIONS AND METHODS FOR SUPPRESSING REACTIVITY TO MULTIPLE FOOD ALLERGENS
WO - 07.07.2022
Clasificación Internacional A61K 39/07 Nº de solicitud PCT/US2021/065576 Solicitante THE REGENTS OF THE UNIVERSITY OF MICHIGAN Inventor/a BAKER, JR., James R.
The disclosure is directed to compositions and methods for inhibiting an allergic reaction to two or more food allergens. The compositions comprise a nanoemulsion and at least one of the two or more food allergens.

45.20220211833NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC AND OTHER CANCERS
US - 07.07.2022

Clasificación Internacional A61K 39/00 Nº de solicitud 17692264 Solicitante Immatics Biotechnologies GmbH Inventor/a Andrea MAHR
The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

# Patentes registradas en la United States Patent and Trademark Office (USPTO)

*Results Search in US Patent Collection db for: (ABST/vaccine AND ISD/20220701->20220711), 6 records.*

| | PAT. NO. | Title |
|---|---|---|
| 1 | 11,376,325 | Method of inducing an immune response using an expression construct and GLA |
| 2 | 11,376,324 | Sting activating nanovaccine for immunotherapy |
| 3 | 11,376,323 | Mixtures of polysaccharide protein pegylated compounds |
| 4 | 11,376,320 | Immunogenic and vaccine compositions against SARS-CoV-2 |
| 5 | 11,376,319 | Recombinant H7N9 subtype avian influenza virus, inactivated marked vaccine and preparation method thereof |
| 6 | 11,376,281 | Peptides and combination of peptides of non-canonical origin for use in immunotherapy against different types of cancers |

  

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.*

*Edición: Annia Ramos Rodríguez* aramos@finlay.edu.cu
*Ma. Victoria Guzmán Sánchez* mguzman@finlay.edu.cu
*Randelys Molina Castro* rmolina@finlay.edu.cu
*Irina Crespo Molina* icrespo@finlay.edu.cu
*Yamira Puig Fernández* yamipuig@finlay.edu.cu
*Rolando Ochoa Azze* ochoa@finlay.edu.cu

FINLAY EDICIONES

  